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Chapter One
Introduction to Contrast Agents for Magnetic Resonance Imaging
1.1 Introduction
To obtain a doctoral degree in chemistry, I have investigated the physical and
imaging-relevant properties of Eu2+-containing cryptates using a variety of techniques
including magnetic resonance imaging (MRI),
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O NMR spectroscopy, and electron

paramagnetic resonance (EPR) spectroscopy. In addition, I examined the stability of these
cryptates towards transmetallation in the presence of biologically relevant metal ions.
Finally, I studied the binding of a cryptate to human serum albumin to study the relaxivity–
molecular weight relationship for Eu2+-containing complexes. The results from all of these
studies will be discussed throughout this thesis. This chapter describes the introductory
material that will be necessary to appreciate my results. Specifically, I will describe ultrahigh field strength MRI, the properties of MRI contrast agents, and Eu2+-containing
cryptates as candidates for use as contrast agents for MRI.
1.2 Ultra-High Field Strength MRI
MRI uses radiofrequency and magnetic fields to probe the chemical environment of
water protons to produce images. This imaging technique is noninvasive because it does
not require cutting or use harmful ionizing radiation to acquire images of the inside of
opaque objects. The utility of this technique to study anatomical features stems from its
inherent high spatial resolution [0.2–0.8 mm at 1.5–3 Tesla (T)]1 which makes MRI a
widely used imaging technique for clinical and preclinical research as well as diagnostic
medicine. Most medical imaging is performed at 1.5 and 3 T; however, working at ultrahigh fields (≥7 T) enables even higher resolution images (0.05 mm at 7 T) that can be used
to study fine anatomical structures including senile plaques in Alzheimer’s disease.1
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Furthermore, ultra-high fields enable the use of shorter acquisition times relative to
working at lower field strengths (Figure 1.1).1,2

Figure 1.1. MR images of a human brain taken at (a) 1.5 and (b) 7 T. Improvement in
spatial resolution can be seen at 7 T that enables the detection of a cerebral microbleed
(noted by the arrow). Reprinted with permission from ref. [3] Copyright (2011) John Wiley
and Sons.
1.3 Contrast Agents for MRI
Sometimes the contrast brought by MRI is not enough to differentiate pathological
tissues from the surrounding healthy tissues. Therefore, contrast agents are used to further
enhance image contrast by catalytically reducing the relaxation time of water protons in the
vicinity of the contrast agents (Figure 1.2).
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Figure 1.2 MR images of a mouse brain with an U87MG tumor taken before injection,
directly

after

injection,

and

2

min

after

the

injection

of

gadolinium(III)

diethylenetriaminepentaacetate (GdDTPA). The increased permeability of the vasculature
in the tumor allows GdDTPA to diffuse into the tumor and resulted in the contrast
enhancement. Reprinted with permission from ref. [4] Copyright (2006) Elsevier.
The ability of a contrast agent to influence the longitudinal relaxation rate (1/T1) of
water protons is known as relaxivity (r1) and is expressed in units of mM–1 s–1. Relaxivity
can be determined as the slope of a plot of proton longitudinal relaxation rate, 1/T1, versus
the concentration of contrast agent. The relaxivity of common contrast agents, including
Gd3+-based contrast agents, decreases as field strength increases, and in the ultra-high field
regime, the efficiency of common contrast agents decreases considerably.6 This
observation is demonstrated by the work of Weinmann and coworkers who measured the
relaxivity of several Gd3+-based complexes including the clinically approved
gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (GdDOTA) and 5[trisodium{4-(R)-[(4,4-diphenylcyclohexyl)phosphanooxymethyl]-3,6,9-tri-aza-3,6,9-tris
(methoxycarbonyl)undecanedioato}gadolinium(III) (MS-325)–albumin at different field
strengths (Figure 1.3).7 The relaxivity values decrease as the field strength increases,
indicating that these Gd3+-based complexes become less efficient at higher fields.
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Figure 1.3 Plots of relaxivity (37 °C, plasma) versus field strength for GdDOTA (left) and
MS-325–albumin (right).7
1.4 Factors Influencing the Efficiency of MRI Contrast Agents
There are several parameters that are crucial to increasing relaxivity including the
number of inner-sphere water molecules or the number of water molecules that is directly
bound to the metal ion, q; the water-exchange rate or the rate at which inner-sphere water
exchanges with bulk water, 1/τm; and the rotational-correlation rate or the rate at which the
complex tumbles in solution, 1/τR. The way these molecular parameters affect the observed
relaxivity of a contrast agent is well described by several intertwined equations known as
the Solomon–Bloembergen–Morgan (SBM) equations (Eqs 1.1–1.4). It is clear from the
SBM equations that relaxivity is influenced by numerous parameters.
Eq 1.1

Eq 1.2
Eq 1.3
Eq 1.4

(
(

)(
)

(

)

)
( ) (

)
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For example, observed relaxivity is linearly dependent on the number of bound water
molecules (Eq. 1.2). Therefore, to increase relaxivity, it is desirable for q to be as large as
possible. However, increasing the number of inner-sphere water molecules by decreasing
the denticity of the ligand generally increases the chance of demetallation. Because
unchelated Gd3+ is toxic, the value of q needs to be as high as possible as long as the
complex is stable to demetallation. In addition to q, the relaxivity of a Gd3+-containing
complex is dependent on the bound-water-residency lifetime, τm, which is the reciprocal of
the water-exchange rate. To increase relaxivity, the optimum value of the water-exchange
rate between the inner-sphere water and the bulk solvent water should be slow enough for
the metal ion to effectively influence the relaxation of water protons, but fast enough to
allow the metal ion to interact with many water molecules. The water residency lifetime of
bound water is interdependent on other parameters that include the rate at which the Gd3+containing complex rotates in solution. This rotational correlation rate is usually the
limiting factor influencing relaxivity for small molecules including GdDOTA.
To obtain maximum relaxivity, the molecular parameters need to be simultaneously
tuned so that the sum of the rotational correlation rate (1/τR), water-exchange rate (1/τm),
and the electronic spin relaxation rate (1/T1e) is equal to that of the proton Larmor
frequency, ωI, or the frequency at which the proton’s magnetic moment precesses at a
given magnetic field strength (Eq 1.4). Because proton Larmor frequency is dependent on
magnetic field strength (Figure 1.4), the optimum values for these molecular parameters
also change as a function of field strength.
Eq 1.5

Proton Larmor Frequency ωI,
(s–1)

6

4×109
4E+09

0
0

8
Field Strength, B (T)
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Figure 1.4 Plot of proton Larmor frequency versus magnetic field strength. The proton
Larmor frequency values were calculated using Eq 1.5.
There are two strategies that have been used to optimize values for rotational
correlation rate (1/τR) and water-exchange rate (1/τm): (1) modifying the ligand such that
the paramagnetic complex can bind to macromolecules thereby controlling the rotational
correlation rate of the complex8 and (2) introducing steric bulk in the water-binding site in
the metal complex to enable control of the water-exchange rate of the complex.9 Because
most Gd3+-containing complexes have slow water-exchange rates (~106 s–1),10 I took a
slightly different approach—changing the metal from Gd3+ to Eu2+ and adapting the ligand
modification strategies that work for Gd3+-based contrast agents. I used Eu2+ as an
alternative to Gd3+ to test the hypothesis that Eu2+ is an efficient contrast agent for ultrahigh-field-strength MRI. Eu2+ is isoelectronic with Gd3+, but differs in some molecular
properties, including electronic spin relaxation rate and charge density, which in turn affect
water-exchange rates. These molecular properties of Eu2+ can be tuned by changing the
ligand structure using coordination chemistry principles based from the previous work with
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Eu2+-containing complexes.11 The second chapter of my dissertation surveys the recent
developments in the coordination chemistry of Eu2+ and applications of Eu2+-containing
complexes including the potential use of these complexes as contrast agents for MRI.
1.5 Eu2+-containing [2.2.2]cryptates
A promising feature of Eu2+ that makes this ion an excellent candidate for use as a
contrast agent for MRI is its lower charge density relative to Gd3+. A lower charge density
makes Eu2+ to have a faster water-exchange rate than Gd3+ (Table 1.1). However, research
on Eu2+ chemistry in aqueous solution is limited because of the oxidative instability of
Eu2+ in the presence of molecular oxygen. It has been demonstrated in the work of Allen
and coworkers, where I was actively involved in synthesizing starting materials, that the
divalent state of Eu can be stabilized using modified macrobicyclic ligands known as
cryptands. Chelation of Eu2+ results in the formation of cryptates, which is the term for
metalated cryptands. Using coordination chemistry principles—including Lewis basicity,
steric bulk, cavity size, and hard–soft acid–base theory—the most oxidatively stable,
aqueous Eu2+ complex reported was developed: the benzotetrathia[2.2.2] Eu2+-containing
cryptate that is more oxidatively stable than Fe2+ in hemoglobin (Figure 1.5).11
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Table 1.1 Comparison of Eu2+ to Gd3+ in terms of charge, ionic radius, and waterexchange rate.
Eu2+

Gd3+

Charge

+2

+3

Radius (pm)12

125

108

Water-exchange rate (109 s–1),10 [M(H2O)8]x

4.4

0.8

Water-exchange rate (109 s–1),10 [M(DTPA)(H2O)]x

1.3

0.033

M = Gd3+ or Eu2+; x is the charge of the complex

Figure 1.5 Plot of the anodic peak potentials of Eu2+ cryptates 1.1–1.6, the Eu2+ aqua ion,
Fe2+ in hemoglobin, and water. A more positive potential means increased oxidative
stability. Anodic peak potentials are reported as mean ± standard error of at least three
measurements relative to Ag/AgCl.11
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In addition to stabilizing the divalent state of Eu, the unfunctionalized Eu2+containing [2.2.2]cryptate (Figure 1.6) was reported to have two inner-sphere water
molecules and fast water-exchange rate (~108 s–1).13 These favorable properties prompted
me to hypothesize that Eu2+-containing crypates would be candidates for contrast agents at
ultra-high field MRI. I investigated the contrast-enhancing ability of Eu2+-containing
cryptates at different field strengths, temperature, and pH because these factors influence
the relaxivity of contrast agents. The efficacy of Eu2+-containing cryptates at different
temperatures and field strengths as well as the physical properties of Eu2+-containing
cryptates are presented in the third chapter of this thesis.

Figure 1.6 Chemical structure of the unfunctionalized Eu2+-containing [2.2.2]cryptate 1.7.
Another critical feature that should be considered for complexes to be used as
contrast agents for MRI is their stability towards demetallation. For contrast agents to be
safe, they should be kinetically inert for at least long enough to be excreted. The stability
towards demetallation is important for these Eu2+-containing cryptates because
uncomplexed Eu2+ oxidizes easily, and Eu3+ is toxic.14 One possible pathway for
dechelation of Eu2+ from a complex is by transmetallation induced by other ions. Ions that
are found in blood plasma that could exchange with Eu2+ include Ca2+, Mg2+, and Zn2+.14
These ions are of particular concern because of their abundance and their tendency to be
complexed by ligands. Therefore, I examined the stability of several Eu2+-containing
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cryptates towards transmetallation in the presence of Ca2+, Mg2+, and Zn2+, and the details
of the transmetallation studies are presented in the fourth chapter of this document.
The transmetallation studies demonstrated that amine-containing cryptates are inert
to transmetallation, and because relaxivity tends to increase with molecular weight for
these cryptates, I hypothesized that increasing the molecular weight by binding to human
serum albumin produces a more efficient contrast agent. The fifth chapter of this thesis
discusses the effect of the interaction of biphenyl cryptate 1.8 (Figure 1.7) with albumin
and the resulting relaxometric properties of the cryptate.

Figure

1.7

Chemical

structure

of

the

biphenyl-functionalized

Eu2+-containing

[2.2.2]cryptate 1.8.
The final chapter summarizes my graduate research and discusses the future
directions to establish relaxivity–molecular weight relationship for the Eu2+-containing
cryptates using macromolecular and supramolecular systems and to evaluate the toxicity
profile of these cryptates to assess their potential use for in vivo applications.
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2.1 Introduction
2.1.1 Properties of Eu2+
Among the divalent lanthanides, Eu2+ has the most accessible divalent oxidation state
because of its half-filled 4f7 electronic configuration and, consequently, a high stabilization
from exchange energy (Figure 2.1).1 While Eu2+ is the most accessible of the divalent
lanthanides, outside of the solid state it has a propensity to oxidize [reduction potential,
Euo(Eu3+/Eu2+) = –0.35 V vs normal hydrogen electrode (NHE)],2 which necessitates
handling under an inert atmosphere. Four decades ago, there were only a few discrete Eu2+containing complexes reported. Most of these complexes were halides, chalcogenides, and
organometallic compounds that are generally insoluble in organic solvents such as
tetrahydrofuran (THF) because of the formation of extended structures.3

Figure 2.1 Relative reduction potentials for Ln3+→Ln2+ (V vs NHE).2
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Despite oxidation and oligomerization presenting obstacles to the preparation and
characterization of Eu2+-containing complexes, the interesting catalytic, photophysical, and
magnetic properties of this ion have spurred a great deal of research. The unique properties
of Eu2+ are influenced largely by the spacing of the energy levels of the 4f and 5d orbitals
and the reducing properties of the ion.
The f orbitals make the electronic properties of Eu2+ unique compared to elements
in the d block. For example, using spectroscopic techniques, Adin and Sykes demonstrated
that electron transfer from f orbitals is more difficult than from d orbitals.4 They observed a
rate constant for the reaction of Eu2+ with V3+ of 0.013 M–1 s–1 (1.0 N HClO4, 25 °C, ionic
strength of 2.0 M), while the reaction of Cr2+ with V3+ under the same conditions is 0.85
M–1 s–1.4 The smaller rate constant observed for Eu2+ relative to Cr2+ can be attributed to
the valence 4f orbitals being shielded from the environment by the electrons in the fully
occupied 5s and 5p orbitals. An additional influence of the f orbitals is exemplified by the
photophysical properties of Eu2+ that stem from the lowest-energy and first-excited-state
configurations of 4f7 and 4f65d1, respectively.5 While the 4f orbitals of Eu2+ remain largely
unperturbed by the presence of ligands, the energy of the 5d orbitals is influenced readily
by ligands. Consequently, the luminescence properties of Eu2+ can be tuned using
coordination chemistry, and the characteristic emission properties of this divalent ion
include a broad emission band (390–580 nm)6 and a short radiative lifetime (~1 µs) that are
attributed to the Laporte allowed 4f65d1→4f7 transitions.5 In addition to these allowed
transitions, sharp emission bands, which appear between 354 and 376 nm,7,8 and longer
radiative emission lifetimes (~1 ms) are observed that correspond to the Laporte forbidden
4f→4f transitions, similar to those observed in the Eu3+ ion.5 Beyond the unique
luminescence properties of Eu2+, the f orbitals are responsible for the interesting magnetic
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characteristics of this divalent ion that include a high magnetic moment (7.63–8.43 µB)
associated with seven unpaired electrons in an 8S7/2 ground-state configuration.3,9
In addition to the desirable optical and magnetic properties of Eu2+, this ion
displays interesting redox chemistry. Divalent lanthanides including Eu2+ act as oneelectron reductants, and detailed discussions of the reductive chemistry of divalent
lanthanides were published by Evans in 2000 and 2002.2,10 Since then, research efforts
have been directed toward developing Eu2+-containing species that act as multielectron
reductants in synthetic chemistry.11 Additionally, there is interest in studying the influence
of ligands on the redox properties of Eu2+.12
2.1.2 Early Eu2+ Complexes
Discrete Eu2+-containing complexes were reported as early as 1964.13 However, the
number of these complexes is small relative to their Eu3+ analogues, which form air-stable
complexes with most electronegative atoms such as oxygen and nitrogen, partially because
Eu3+ is a hard Lewis acid. Eu2+ is a softer Lewis acid than Eu3+ because of its lower charge
density; consequently, Eu2+-containing complexes often include ligands with relatively soft
atoms such as carbon and phosphorous.
Among the first discrete Eu2+-containing complexes prepared was the metallocene-like
complex Cp2Eu, where Cp is cyclopentadiene. This complex did not garner much interest
because of its insolubility in polar organic solvents such as THF.14 This insolubility was
ascribed to a polymerization that can be prevented with the use of bulkier ligands.9,14,15
Templeton and coworkers were able to isolate crystals from THF or toluene of Cp*2Eu,
2.1, where Cp* is methyl-substituted Cp (Figure 2.2).9 Evans and coworkers investigated
the bond characteristics and the electronic spin–spin paramagnetic relaxation rate of Eu in
Cp*2Eu(THF), 2.2, and Cp*2Eu(THF)(Et2O), 2.3. The Eu–ligand bonds of 2.2 and 2.3 are
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ionic in character as indicated by the isomer shifts of these complexes: from

151

Eu

Mössbauer spectroscopy, a technique used to study the oxidation state and the local
environment of Eu in the solid state, the shifts of 2.2 and 2.3 are not different from those of
ionic Eu2+ halide complexes.16 Moreover, the data obtained from the spherical relaxation
model fits of the 151Eu Mössbauer spectra of the 2.2, 2.3, and [Cp*Eu(THF)2(µ-I)]2, 2.4, in
the solid state indicate that the Eu–Eu distances affect the electronic spin–spin
paramagnetic relaxation of these complexes, with longer Eu–Eu distances leading to
slower spin–spin relaxation rates.16 In addition to Cp*, the sterically demanding ligand
bis(trimethylsilyl)amide, [((CH3)3Si)2N]–, was used as a precursor in preparing Eu2+
complexes. The six-coordinate complex [((CH3)3Si)2N]2Eu(CH3OCH2CH2OCH3)2, 2.5,
and the four-coordinate complex [((CH3)3Si)2N]2Eu(bpy), 2.6, where bpy is 2,2’bipyridine, are both soluble in THF, pentane, toluene, and 1,2-dimethoxyethane (DME).3
In general, the problem of insolubility in hydrocarbons is addressed using sterically
demanding ligands to increase hydrophobicity and to prevent the formation of coordination
polymers.9,14,15
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Figure 2.2 Structures of Eu2+-containing complexes 2.1–2.15.
Phosphine complexes of Eu2+ have been investigated since the early 1980s and display
unique structural and electronic properties.17–19 In some cases, phosphorous-containing
ligands form dative bonds with Eu2+ in the presence of oxygen-containing bases.20
Templeton and coworkers reported the synthesis of phosphine complexes of Eu2+: in their
procedure, NaEu[N(Si(CH3)3)2]3 was prepared from EuI2 and NaN(Si(CH3)3)2 in diethyl
ether, and the relatively weak donor ligand [N(Si(CH3)3)2]– was displaced by a
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phosphorous-containing ligand such as 1,2-bis-(dimethylphosphino)ethane (DMPE) to
give a complex with an empirical formula of Eu[N(Si(CH3)3)2]2(DMPE)1.5.19 Another
Eu2+-containing phosphine complex was reported by the same group with Cp* in place of
[N(Si(CH3)3)2]–. The resulting complex, EuCp*2(DMPE), 2.7, was not soluble in
noncoordinating solvents, potentially because of the role of DMPE in bridging complexes
to form coordination polymers. To reduce the potential for aggregation, ethylene-bridged
DMPE was replaced with methylene-bridged 1,2-bis-(dimethylphosphino)methane
(DMPM).21 The resulting complex EuCp*2(DMPM), 2.8, was isolated, but analogous
complexes with monodentate phosphines such as P(CH3)3 or P(n-Bu)3 were not reported,
likely because the steric bulk of these phosphines prevented the formation of a
coordinatively saturated metal ion.21 Another Eu2+-containing phosphine complex was
reported by Rabe and coworkers.18 Their four-coordinate, homoleptic Eu2+-containing
phosphine complex Eu[(µ-P(t-Bu)2)2-Li(THF)]2, 2.9, assumes a heavily distorted
tetrahedral geometry. The oxidation state of Eu in the complex was confirmed by
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Eu

Mössbauer spectroscopy with an isomer shift of –11.7 mm s–1 as opposed to isomer shifts
of 0–1 mm s–1 for compounds that contain Eu3+ (Figure 2.3).18 One interesting feature of
this complex is that an alkali ion, Li+, interacts with phosphorous in P(t-Bu)2 and oxygen in
THF similar to the complex NaEu[N(Si(CH3)3)2]3 where Na+ interacts with the nitrogen of
[N(Si(CH3)3)2]–.15,18 Also, an agostic interaction between Eu2+ and the tert-butyl groups in
P(t-Bu)2 was observed in 2.9.18 The authors postulated that this interaction is driven by the
tendency of the metal to form a coordinatively saturated environment and also by crystal
packing forces because this interaction is only observed in the solid state.15,18
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Figure 2.3
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Eu Mössbauer spectrum of 2.9 at 4.2 K. Reprinted with permission from G.

W. Rabe, G. P. A. Yap, A. L. Rheingold, Inorg. Chem. 1997, 36, 3212–3215. Copyright
1997 American Chemical Society.
In addition to the softer C- and P-containing ligands, polyoxadiazamacrobicyclic
ligands (cryptands) form stable complexes (cryptates) of Eu2+, 2.10–2.13, which were first
reported in the late 1970s. Cryptands are used to encapsulate Eu2+ to oxidatively stabilize
this ion and enable studies of the luminescence properties of Eu2+. Gansow and coworkers
demonstrated the oxidative stabilization of Eu2+ using cyclic voltammetry when the ion is
bound by cryptands.22 This stabilization was attributed to a good fit of the Eu2+ ion in the
cryptand cavity,22 and the thermodynamic stability constants (log K) for some Eu2+containing cryptates were reported by Burns and Baes to be 10.2–13.0.23 Besides the
thermodynamic properties of these cryptates, these Eu2+-containing cryptates are
substitutionally inert towards Na+, Ba2+, Ca2+, Mg2+, Zn2+, and tetraethylammonium
cations.24,25 Beyond stabilizing the Eu2+ ion thermodynamically and kinetically, cryptands
also exclude a large number of solvent molecules from the inner-sphere of the ion. This
solvent exclusion is important because coordinated solvent molecules quench the
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luminescence of Eu2+, thus this ion does not exhibit strong luminescence in aqueous
solution at room temperature when not chelated.26
In the 1990s, Eu2+ complexes with a wide variety of ligands were synthesized.
Shore

and

coworkers

reported

Eu2+-containing borohydrides

(NH3)xEu(B10H14),

(CH3CN)2Eu(BH4)2, and (C5H5N)1.8Eu(BH4)2 as precursors for preparing metal
borides.20,27 However, all complexes that contain borohydrides are unstable as solids and
tend to decompose to produce closo-[B10H10]2–.20 The conversion from Eu2+ borohydrides
to Eu2+ borides was performed successfully at high temperatures (>200 °C) under vacuum
to obtain the stable boride phase, EuB6.27 Although Eu2+-containing complexes with
borohydrides as ligands were successfully synthesized, the coordination modes of Eu2+ in
these complexes were not fully explored due to the lack of X-ray crystallographic data. In
addition to Eu2+ borohydrides, Eu2+ selenolates and tellurolates were also prepared. For
example, Eu[ESi(Si(CH3)3)3]2(TMEDA)2, 2.14, and {Eu[ESi(Si(CH3)3)3]2(DMPE)2}2(µDMPE), 2.15, were reported by Arnold

and coworkers where TMEDA is

(CH3)2NCH2CH2N(CH3)2 and E is Se or Te.28 The crystal structure of 2.15 reveals a sevencoordinate Eu2+ ion that is bridged by DMPE to form a dimeric complex that was not
observed for the TMEDA-containing complex. The difference in coordination chemistry of
the two complexes was attributed to the larger covalent radius of P relative to N and,
consequently, a less crowded metal center in complex 2.15.28
The seminal studies of the coordination chemistry of Eu2+ from the 1960’s through
the 1990’s built a foundation for the design of new ligands that will be driven by the
functions of the resulting Eu2+-containing complexes. While Eu2+-containing clusters and
polymers are reported in the literature,29–33 these compounds are not described in this
chapter because the focus of this chapter is recent advances in the coordination chemistry
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of discrete Eu2+ complexes. Synthetic strategies reported in the 21st century are presented
followed by a description of the reactivity and applications of the resulting Eu2+-containing
complexes.
2.2 Synthesis of Recent Eu2+-Containing Complexes
The rapid increase in the reporting of Eu2+-containing complexes over the last two
decades has resulted in the publication of several synthetic pathways to prepare these
complexes (Scheme 2.1). These methods fall into three categories based on the europiumbased starting materials used: metallic europium; europium(III) salts including halides,
triflates, oxides, or nitrates; or europium(II) halides. This section is organized based on
these three types of starting materials: oxidation of Eu metal, reduction of Eu3+, and
metathesis of Eu2+.
Scheme 2.1 Synthetic methods for obtaining Eu2+-containing complexes arranged by
source of europium where L is a ligand, N is either Hg or Sn, and M is an alkali metal ion.

2.2.1 Oxidation of Eu0
Oxidation of Eu metal can be accomplished by activation of Eu0 using Hg, iodine, or
liquid ammonia; redox transmetallation; or pseudo-Grignard formation. It is crucial to
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perform this type of synthesis under an inert atmosphere because Eu metal will oxidize
uncontrollably in air to produce mixtures of Eu2+- and Eu3+-containing complexes.
Syntheses of Eu2+ complexes from Eu0 often require activation. Mercury, which
activates Eu0 through amalgamation, was used to prepare the homoleptic and tetranuclear
Eu2+ complex Eu4[(t-Bu)2pz)]8, 2.16, where (t-Bu)2pz is 3,5-di-tert-butylpyrazolate
(Figure 2.4).34 Structural elucidation of the linear complex 2.16 revealed different
coordination modes (η2, µ-η5:η2, and µ-η2:η2) for the pyrazolates to Eu2+. The outer Eu2+
ions are bonded in a η2 fashion by the two terminal pyrazolates; a µ-η5:η2 coordination
mode is observed for the four pyrazolates that bridge the inner and outer Eu2+ ions; and a
µ-η2:η2 binding mode is exhibited by the two pyrazolates that bridge the two inner Eu2+
centers.34
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Figure 2.4 Structures of Eu2+-containing complexes 2.16–2.19, 2.21–2.28, 2.30–2.35,
2.38, and 2.40 that were prepared from the oxidation of Eu0.
An alternative to Hg as an activating agent is iodine, which was reported to be crucial
in the preparation of several lanthanide-based complexes including the dimeric
[Eu(Odip)(µ-Odip)(THF)2]2, 2.17, where Odip is 2,6-diisopropylphenolate.35 In addition to
mercury and iodine, dissolution in liquid ammonia can be used in the activation of Eu 0.
Such is the case in the preparation of Eu2+-containing alkoxide Eu[OC6H3-2,6-(t-
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Bu)2]2(THF)3·0.75C7H8, 2.18, and aryloxides [Eu4(μ-OC10H7)6(OC10H7)2(THF)10]·2THF,
2.19, and Eu(OC6H4OCH3)2, 2.20.36–38 Activation of Eu0 was also employed using liquid
ammonia for the synthesis of {Eu2[(t-Bu)2pz)]4(THF)2} that is characterized by having
centrosymmetric Eu2+ centers bonded in µ-η2:η5 and η2 modes by the bridging and terminal
pyrazolate ligands, respectively.39 These coordination modes can also be found in
pyrazolate-based Eu2+ complex 2.16 and demonstrate the ability of pyrazolate ligands to
coordinatively saturate Eu2+. Liquid ammonia was also used in the one-pot synthesis of the
organohydroborate complex of Eu2+ (THF)4Eu{(μ-H)2BC8H14}2, 2.21, that features an
agostic interaction between Eu2+ and a hydrogen atom in one of the hydroborate ligands.
Structural and IR data suggest the presence of agostic interaction in solution and solid
state, and this interaction may have influenced the cis arrangement of the hydroborate
ligands in the octahedral complex.40
The preparation of Eu2+ complexes through redox transmetallation sometimes uses
mercury- and tin-based complexes as oxidants, and activating agents such as Hg are used
to

improve the

yields

of this

type of

synthesis.

The preparation of

the

(perfluoroaryl)europium(II) complex Eu(C6F5)2(OC4H8)5, 2.22, entails the oxidation of Eu0
using bis(pentafluorophenyl)mercury, Hg(C6F5)2, in THF. Complex 2.22, characterized by
a pentagonal bipyramidal geometry with axial C6F5 groups and five THF molecules in the
equatorial position, has relatively long Eu–C bonds (2.82 Å) that are likely due to the
inductive electron-withdrawing effect of the fluorine substituents of the two phenyl
groups.41 The same oxidant, Hg(C6F5)2, was used to prepare the homoleptic and dinuclear
{Eu(i-Pr2pz)2(i-Pr2pzH)2}2, 2.23, where i-Pr2pz is 3,5-diisopropylpyrazolate. An x-ray
crystal structure of the pyrazolato Eu2+ complex 2.23 shows a different coordination mode
(µ-η5:η1) to Eu2+ by the bridging 3,5-diisopropylpyrazolates centers. This coordination

26
mode of the bridging pyrazolates in addition to the η1 binding mode of the terminal
pyrazolates was ascribed to intramolecular hydrogen binding.42 It is worth noting that
redox transmetallation reactions carried out in nonpolar solvents including toluene (for
example, in the preparation of complex 2.23) can produce homoleptic Eu2+ complexes. In
addition to complexes 2.22 and 2.23, Hg(C6F5)2 was used as oxidant in the preparation of
Eu2+-containing complexes with triazanides as ligands [Dmp(Tph)N3EuC6F5], 2.24, and
[Eu{N3Dmp(Tph)}2], 2.25 where Dmp is 2,6-(2,4,6-(CH3)3C6H2)2C6H3 and Tph is 2(2,4,6-i-Pr3C6H2)C6H4. Of particular note are the coordination modes of the terphenyl and
biphenyl groups in complexes 2.24 and 2.25 that exhibit -arene–Eu interactions with Eu–
C distances of 3.088–3.233 and 3.011–3.311 Å in complex 2.24 and 2.25, respectively. In
complex 2.24, both the mesityl ring of the terphenyl group and the triisopropylphenyl ring
of the biphenyl moiety show an 5 interaction with the metal, whereas in complex 2.25, the
mesityl rings of terphenyl groups exhibit 5 and 3 binding modes. The assignment of
hapticity was based on the shortest metal–centroid separation or the smallest angle of the
M–centroid vector and the normal of the arene plane.43,44
When Hg(SCN)2 was used as oxidant, [Eu(NCS)2(DME)3], 2.26, was obtained from
redox transmetallation with Eu0 in DME, and bimetallic [Eu(NCS)2(THF)4]2, 2.27, was
obtained when THF was used as solvent. The crystal structure of the eight-coordinate 2.26
shows configurational isomers, and the relative amount of each isomer is dependent on
temperature. Racemic mixtures in a single crystal can be obtained at lower temperature (5
°C) while a mixture of enantionamerically pure Λ (left hand) or Δ (right hand) products
was observed in a single crystal at room temperature.45 The coordination environment in
2.27 features bridging two thiocyanate ligands and terminal THF molecules, adapting a
distorted pentagonal bipyramidal geometry in each Eu2+ center.
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Besides mercury-based oxidants, trialkyltin(IV) compounds were explored for redox
transmetallation with Eu0. Either the trivalent [Eu3+(Ph2pz)3(DME)2]·2DME, 2.28, or the
divalent cis-[Eu2+(Ph2pz)2(DME)2], 2.29, can be made from the reaction of
Sn(CH3)3(Ph2pz), where Ph2pz is 3,5-diphenylpyrazolate, with Eu0 in DME by changing
the amount of excess Eu0.46,47
In contrast to redox transmetallation, the route toward the formation of a pseudoGrignard compound has been successful in preparing Eu2+ complexes even without the use
of Hg, iodine, or ammonia. Thiolate-containing complex Eu(SAr*)2(THF)0.5, 2.30, where
Ar* is 2,6-(2,4,6-(i-Pr)3C6H2)2C6H3 was prepared from Eu0, Ar*SH, and 2iodobenzotrifluoride.48 This thiolate complex is characterized by η6-π interactions of Eu2+
with two o-2,4,6-triisopropylphenyl rings of the terphenyl groups as evidenced by IR
spectroscopy and X-ray crystallography.48 Another example of a Eu2+-containing complex
that shows η1-π interactions with Eu2+ and was prepared from europium metal is
Eu(Dpp)(THF)2, 2.31, where Dpp is 2,6-Ph2C6H3. Complex 2.31 was synthesized from Eu0
and DppI in THF and exhibits a distorted tetrahedral geometry with two aryl ligands and
two THF molecules.49
While the oxidation of Eu0 through activation of the metal surface, redox
transmetallation, and formation of pseudo-Grignard compounds are used to prepare
homometallic Eu2+ complexes, charged-separated and neutral heterobimetallic Eu2+containing complexes can also be synthesized from Eu0. Treatment of Eu0 and another
lanthanide metal (Y0, Nd0, or Ho0) with 2,6-diphenylphenol (OHdpp) at elevated
temperature (190 °C) in the presence of Hg yielded charged-separated complexes,
[Eu2(Odpp)3][Y(Oddp)4],

2.32;

[Eu2(Odpp)3][Nd(Oddp)4],

2.33;

and

[Eu2(Odpp)3][Ho(Oddp)4], 2.34. The Eu2+ centers in the [Eu2(Odpp)3]+ are bridged by
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aryloxide ligands and have coordination modes of η4:η2:η1 and η1:η6:η3 with π-arene–Eu
interactions.50 In contrast to the charged-separated complexes, heterobimetallic complexes
[CaEu(Oddp4)], 2.35; [SrEu(Oddp)4], 2.36; and [BaEu(Oddp)4], 2.37, were produced upon
reaction of Eu0 and an alkaline-earth metal (Ca0, Sr0, or Ba0) with OHdpp at high
temperatures (210–235 °C). However, when Eu0 was reacted with HOdpp in the presence
of MOdpp (M = Na0, K0, and Li0) at elevated temperature (210 °C), heterobimetallic Eu2+containing complexes [NaEu(Oddp)3]·PhCH3, 2.38, and [KEu(Oddp)3]·2.5PhCH3, 2.39,
and the mixed-valent complex [Eu2(Oddp)3][Eu(Oddp)4], 2.40, were obtained. These
heterobimetallic complexes also show π-arene–Eu interactions that coordinatively saturate
Eu2+. The coordination mode of the Eu2+ center is similar for 2.35 and 2.36 (η2:η3) while a
different binding mode was observed in 2.37 (η3:η5). The coordination modes in the Eu2+containing complexes with alkaline metals are η4:η2:η1 (complex 2.38) and η3:η1:η1
(complex 2.39) and are similar to that of [Eu2(Odpp)3]+ in the charged-separated
complexes 2.32–2.34.51 Structural data for the [Eu2(Oddp)3]+ unit in 2.40 depict the
aryloxides binding in η1:η4:η2 and η3:η2:η3 fashions.51 Purification of charged-separated or
heterobimetallic complexes requires solvent extraction to remove the unreacted metal and
homometallic coproducts.50,51
Despite of the propensity of Eu metal to undergo uncontrolled oxidation to both Eu2+
and Eu3+, the use of Eu metal can produce modest to excellent yields (23–96%) in the
preparation of Eu2+-containing complexes. Also, activating Eu0 using Hg has been shown
to increase the yield of the desired Eu2+ complexes.
2.2.2 Reduction of Eu3+
The reduction of Eu3+ by either a ligand that is also a reductant or by chemical or
electrochemical methods is more common than the oxidation of Eu metal. Eu3+ halides,
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triflates, oxides, or nitrates are typically used as the precursors for the preparation of Eu 2+containing complexes with a variety of ligands including aryloxides, aminodiboranates,
crown ethers, and cryptands.25,52–58 An example of a Eu2+-containing complex that was
prepared from Eu3+ chlorides with a reducing species is the dinuclear, distorted pentagonal
bipyramidal

complex

{Eu(H3BN(CH3)2BH3)2(THF)2}2,

2.41,

which

used

N,N-

dimethylaminodiboranate as the reductant (Figure 2.5).52 However, the preparation of 2.41
produced mixtures of divalent and trivalent species.52 In contrast, only divalent species
were obtained when EuI2 was used as a precursor instead of EuCl3.52 Qi and coworkers
used Eu3+ chlorides as starting materials and a Na–K alloy as reductant to prepare
[LEu(HMPA)2]2(THF)4, 2.42, where L is 2,2’-methylene bis(6-t-butyl-4-methylphenoxo)
and HMPA is hexamethylphosphoric triamide. Complex 2.42 is characterized by two
phenolate moieties bridging two Eu2+ atoms.53 Each Eu2+ in 2.42 adopts a distorted trigonal
bipyramidal geometry and a slightly asymmetric bridging mode of the phenolate ligand.
This asymmetry is also observed in the bond length of Eu–O, where the axial Eu–O bond
(2.44 Å) is shorter than the equatorial Eu–O bond (2.52 Å).53 Also, the variation of the Eu–
O–C angles in 2.42 have been associated with the existence of agostic interaction in this
coordinatively unsaturated complex.53 In addition to the use of Na–K alloy as a
noncoordinating reductant in the preparation of Eu2+-containing complexes, Zn was used
as reductant in the synthesis of complexes 2.10 and Eu2+–18-crown-6, 2.43, from Eu3+
triflate.54 The reduction of Eu3+ by Zn in the presence of 18-crown-6 or [2.2.2]cryptand
was monitored using the absorption bands at 250 and 330 nm, which were assigned to the
Eu2+ species.54 Additionally, Eu3+ oxides serve as starting materials for preparing Eu2+containing complexes using electrochemical reduction. For example, Eu2O3 was reduced
electrochemically in the syntheses of the Eu2+ complex of benzo-18-crown-6 and of
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triethanolamine.55,56 With the reduction of Eu3+ strategy, our laboratory prepared several
Eu2+-containing cryptates, 2.10, 2.11, and 2.44–2.47.57 In general, the advantage of using
the reduction approach is that the metal source is air-stable, so the problem of surface
oxidation is avoided. Nevertheless, the possibility of incomplete reduction of Eu3+ can
limit the yield and purity of the desired Eu2+-containing complexes.

Figure 2.5 Structures of Eu2+-containing complexes 2.41–2.47, which were synthesized by
the reduction of Eu3+.
2.2.3 Metathesis of Eu2+ Complexes
While the other synthetic methods involve redox reactions to obtain Eu2+, the
metathesis approach makes use of Eu2+ halides and alkali metal-containing ligands as
precursors to generate the desired Eu2+-containing complex. The metathesis reaction has
been successful in preparing several Eu2+-containing complexes including the bimetallic
Eu2(Ap*py)3I(THF), 2.48, where Ap*py is deprotonated 6-methylpyridin-2-yl-[6-(2,4,6triisopropylphenyl)pyridin-2-yl]amine;59 a monometallic Eu2+-containing trans-N,N’dimethyl-meso-octaethylporphyrinogen complex, 2.49;60 a Eu2+-containing benzamidinate
complex Eu[PhC(NSi(CH3)3)(2,6-(i-Pr)2NC6H3)]2(THF)2, 2.50;61 a Eu2+ complex with
olefin-substituted cyclopentadienyl ligands [C5(CH3)4Si(CH3)2CH2CH=CH2]2Eu, 2.51;62
the bis(diphosphanylamido complex [{(Ph2P)2N}2Eu(THF)3], 2.52;63 a Eu2+ complex
containing bis(phosphinimino)methanides ligands [{(CH3)3SiNPPh2)2CH}EuI(THF)]2,
2.53;64

the

aminotroponiminate

complex

of

compostion

[{(i-Pr)2ATI}Eu{N-
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(Si(CH3)2}(THF)2],

2.54,

where

(i-Pr)2ATI

is

N-isopropyl-2-

(isopropylamino)troponiminate;65 and a monometallic, heteroleptic [(DIP2pyr)Eu(THF)3],
2.55, where DIP2pyr is 2,5-bis{N-2,6-diisopropylphenyl)iminomethyl}pyrrolyl (Figure
2.6).66 Complexes 2.48–2.55 were prepared from the metathesis reaction of EuI2(THF)x,
where labile THF, iodine, or both are displaced by the desired ligand. Complex 2.50
exhibits cisoid and transoid isomers with respect to the position of coordinated THF.61 The
bidentate diphospanylamides, (Ph2P)2N–, in complex 2.52 are η2 coordinated to the Eu2+
center through the phosphorous and nitrogen. The structure of the bimetallic Eu2+containing complex 2.53 displays the tridentate bis(phosphinimino)methanide ligands
bound to Eu2+ via two nitrogen atoms and a methine carbon atom. Two of these ligands are
coordinated to a Eu2+ center to form a six membered metallacycle with a twist boat
conformation.64 When complex 2.53 was treated with K{CH(PPh2NSi(CH3)2}, the sixcoordinate amido Eu2+-containing complex [{(CH3)3SiNPPh2)2CH}Eu{(Ph2P)2N}(THF)],
2.56, was obtained. As observed in 2.53, the methine carbon was coordinated to Eu2+ in
2.56, and the reported Eu–C (methine carbon) bond lengths were 2.945 Å and 2.878 Å for
complexes 2.53 and 2.56, respectively.64 In contrast to 2.53 where iodine bridged two Eu2+
centers, complex 2.56 is monometallic with a nonbridging iodine atom and THF occupying
the axial positions and the tridentate (DIP2pyr)– ligand that is bound to Eu2+ through its
three nitrogen atoms affording a distorted pentagonal pyramidal complex. As an alternative
to the metathesis reaction of EuI2(THF)x in preparing Eu2+-containing complexes, we used
the commercially available EuI2 to prepare cryptates 2.10, 2.11, and 2.57–2.59.25,58 A
similar europium halide salt was used to generate four-coordinate {Eu[(ArN)2CN(i-Pr)2]2},
2.60, where Ar is 2,6-diisopropylphenyl.67 Roesky and coworkers used a bimetallic Eu2+containing complex [{CH(PPh2NSiMe3)2}Eu(THF)(µ-I)]2 and NaBPh4 as precursors to
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prepare [{CH(PPh2NSi(CH3)3)2}Eu(THF)3]BPh4, 2.61.68 The resulting complex was used
to prepare other Eu2+-containing complexes via metathesis of the labile borate ligand.68
Another example of a borate-containing Eu2+ complex [Cp*(µ-η6:η1-Ph)2EuBPh2], 62, was
prepared from Eu(Cp*)2 in the presence of [Et3NH][BPh4]. The structural motif of
complex 2.62 features one coordinated Cp* and two of the phenyl rings of BPh4– ligand
showing a µ-η6:η1 binding mode, with the ligands arranged in a pyramidal geometry
around the coordination sphere of Eu2+. While density functional theory (DFT) calculations
predicted a trigonal planar shape for complex 2.62, the large size of Eu2+ prefers
intermolecular packing over intramolecular packing in the solid state, and agostic
interactions may also have contributed to this deviation of geometry.69 In general, with the
metathesis approach of preparing Eu2+-containing complexes, the presence of other
oxidation states of Eu is not a problem as long as synthesis is performed under an inert
atmosphere. The success of this third approach of metathesis relies on the completeness of
the displacement of the alkali metal or a practical method of purification to remove
byproduct salts. Steric limitations introduced by the incoming ligand may pose a problem
in preparing the target Eu2+ complex.
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Figure 2.6 Structures of Eu2+-containing complexes 2.48–2.62, which were obtained from
the metathesis of Eu2+-containing complexes.
Each of the three synthetic methods described here have distinct advantages and
limitations, and each route must be carefully considered when choosing a method to
synthesize a new complex. In addition, structural studies of the recently synthesized Eu2+containing complexes presented in this section demonstrate the rich coordination chemistry
of Eu2+. Differences in the coordination environment in Eu2+-containing complexes can be
attributed to steric and electronic effects of the coordinated ligands as well as the size and
electronic properties of Eu2+ that is responsible, in part, to the agostic interaction observed
in some Eu2+ complexes.
The development of other Eu2+-containing complexes in conjunction with the use of
other divalent lanthanides in generating complexes with Ln2+–Ga+ or Ln2+–Al+ (Ln = Sm,
Eu, Yb, or Tm) bonds is an active area of research.70–72 Their applications for use as
reductants are currently being explored.70
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2.3 Applications of Eu2+-Containing Complexes
The growing interest in Eu2+-containing complexes stems from the unique catalytic,
photophysical, and magnetic properties of these complexes. The remainder of this review
describes the use of Eu2+-containing complexes in four different applications.
2.3.1 Reductants
Eu2+ is a one-electron reductant for many systems. However, it was reported that a
bimetallic Sm2+-containing complex has the potential to be a two-electron reductant per
molecule.73 This discovery led to the pursuit of divalent lanthanide species, including Eu2+containing complexes, that could act as multielectron reductants. This active area of
research is important in establishing a more complete understanding in the reduction
chemistry of Eu2+. Lee and coworkers reported a Eu2+-containing complex 2.50 that serves
as a one-electron reductant to a diphenyl dichalcogenide PhSeSePh to produce
{Eu([PhC(NSi(CH3)3)(2,6-(i-Pr)2NC6H3)])2(µ-SePh2)}2, 2.63, in which the two Eu3+
centers are bridged by diphenyl diselenides (Figure 2.7).61 Each Eu3+ ion in 2.63 assumed
a distorted octahedral geometry and was coordinated by two η2-bound benzamidinate
ligands. However, when the same Eu2+-containing bisamidinate complex was allowed to
react with diphenyl ditellurides and iodine, both reactions were unsuccessful, indicating
that the reducing strength of Eu2+ was not sufficient to reduce diphenyl ditellurides and
iodine.61 Also, in the case of the macrocylic ligand system trans-N,N’-dimethyl-mesooctaethylporphyrinogen, the Eu2+-containing complex cannot reduce t-butyl-1,4-diazabuta1,3-diene (t-Bu-DAB).60 However, the analogous Sm2+ complex forms a bimetallic
complex when reacted with t-Bu-DAB.60 The formation of the bimetallic Sm3+ complex
bridged by the reduced [t-Bu-DAB]2– is driven by the reducing power of Sm2+ towards tBu-DAB, but the steric constraints due to the bulky t-butyl moieties makes this reaction
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reversible.60 Because Eu2+ has a more positive Ln2+/Ln3+ oxidation potential (–0.35 V vs
NHE) than Sm2+ (–1.55 V vs NHE), the driving force to form an analogous bimetallic Eu3+
complex is hindered, presumably because the reducing strength of Eu2+ is not sufficient to
reduce t-Bu-DAB. These examples of controlled redox potential could be useful in
selective reductions during multistep syntheses and for developing the first Eu2+-containing
complex that could act as multielectron reductant.

Figure 2.7 Structure of Eu2+-containing reductant 2.63.
An important factor that can control the reducing properties of Eu2+ is the nature of the
ligands. As an example, the reaction with Cp*2Eu(OEt2) with C6F5-substituted
diazabutadiene (DADC6F5)– led to the oxidation of Eu2+ and formation of the radical anion
(DADC6F5)•–.74 The presence of Eu3+ in the resulting complex was characterized by
crystallographic data, magnetic susceptibility measurements, and IR spectroscopy. The
electron-withdrawing characteristic of the C6F5 moiety and its proximity to the metal
center is likely the cause of the facile oxidation of Eu2+. On the other hand, neither
oxidation of Eu2+ nor formation of radical anion was observed when t-butyl-substituted
diazabutadiene was used.74 In general, the diazabutadienyl ligand can have rich redox
chemistry when coupled with Eu2+ by modifying this ligand using substituents of different
electronic properties.
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2.3.2 Polymerization Initiators
As discussed in the previous section, ligands can influence the rich reduction chemistry
of Eu2+ where the resulting complex can play an important role in several applications
including polymer chemistry. In the preparation of polymers, Eu2+-containing complexes
can act as electron-transfer agents to initiate several polymerization processes. An example
of this application is the activity of several Eu2+-containing complexes that contain indenyl
ligands in the initiation of the polymerization of methyl methacrylate (MMA) and εcaprolactone.11,12
2.3.2.1 Methyl Methacrylate Polymerization
Eu2+-containing complexes 2.64–2.73 that contain functionalized indenyl ligands are
used in the polymerization of MMA (Figure 2.8).11,75–77 The activity of these complexes in
polymerizations and the stereochemistries of the resulting polymers are dependent on
temperature and solvent (Figure 2.7). High activity is observed at low temperatures (–30
to –60 °C for complexes 2.64 and 2.65; 0 to –60 °C for complexes 2.66–2.69, 2.72, and
2.73; –30 to –45 °C for complexes 2.70 and 2.71), and these complexes have solventdependent activities. Complexes 2.64, 2.65, and 2.72 have high activities when THF or
dimethoxyethane is used as solvent instead of toluene. Complex 2.66 has high activity in
dimethoxyethane, THF, and toluene; 2.67 show good activity in THF; and complexes 2.68,
2.69, and 2.73 have high activity in dimethoxyethane. The molecular weights of the
resulting MMA polymers were high (up to 443 kDa) at low temperatures indicating that
chain propagation is favored at low temperatures.11,75–77 The mechanism of MMA
polymerization was postulated to initiate through reductive dimerization of MMA via
electron transfer from Eu2+, resulting in the formation of Eu3+ enolates.11,75–77 Propagation
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did not go through an insertion mechanism because the indenyl ligand was not detected on
the polymer chains by 1H NMR spectroscopy.11,76

Figure 2.8 Structure of Eu2+-containing complexes 2.64–2.82, which were used as
polymerization initiators.
The stereochemistry of the MMA polymers is determined by 1H NMR spectroscopy.
The majority of the MMA polymers produced using Eu2+-containing functionalized
indenyl complexes 2.64, 2.65, 2.72 and 2.73 as initiators is syndiotactic.11,77 However,
when complexes 2.66–2.68 were used in dimethoxethane or THF, a 1:1:1 ratio of isotactic,
syndiotactic, and atactic polymers was obtained. But, predominantly syndiotactic polymers
was obtained using 2.66 in toluene, and a decrease in the ratio of syndiotactic to isotactic
polymers was observed using 2.70 when the solvent was changed from THF or
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dimethoxyethane to toluene suggesting a solvent effect influences the stereochemistry of
these polymers. The presence of several tacticities in the synthesized polymers was
attributed to the rac/meso interconversion, which is favored by solvents including THF and
dimethoxyethane.77 While the stereochemistry of the polymers showed solvent
dependency, it is still unclear if this stereoregularity is influenced by the nature of the
initiator, specifically on the metal and ligands. A similar study that uses different initiators
(for example, different divalent lanthanide metal ions or a ligand system other than indene
compounds) could answer this question.
2.3.2.2 Ring-Opening Polymerization of ε-Caprolactone
Eu2+-containing

complexes

2.74–2.79

that

contain

indenyl,

fluorenyl,

and

iminopyrrolyl ligands showed catalytic activity in the ring-opening polymerization of εcaprolactone.12,78–80 With these catalysts, high activity is observed at high temperatures (0
to 30 °C for complexes 2.75 and 2.76; –30 to 60 °C for complex 2.74; 0 to 60 °C for
complex 2.77; and 30 to 60 °C for complexes 2.78 and 2.79), and the activities of these
complexes depend on solvent. Complexes 2.77–2.79 have high activities when THF or
toluene is the solvent; complex 2.74 exhibits high activity in dimethoxyethane, THF, and
toluene; and 2.75 and 2.76 show good activity in toluene. Furthermore, the steric bulk of
the substituents in the ligands may have an effect on the activity of the complexes and the
molecular weights of the resulting polymers. When the silyl substituent in the furfuryl- or
tetrahydrofurfuryl-functionalized indenyl ligands of complexes 2.75 and 2.76 was absent,
no activity using the two complexes was observed. However, it is not clear what the role of
the silyl substituent is in the polymerization process.78 The use of more sterically bulky
ligands in 2.79 relative to the ligands in 2.78 has been implicated to affect the chain
propagation process, thus affecting the molecular weights of the polymers.80 Wang and
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coworkers proposed that the polymerization of ε-caprolactone is initiated by the formation
of Eu3+-containing alkoxyl radical species formed from the oxidation of the Eu2+ metal
center (Scheme 2.2).12 The alkoxyl radical species is believed to take a second Eu2+containing complex and produce a bimetallic Eu3+-containing complex that is bridged by
the opened caprolactone.12 Subsequently, chain propagation occurs when subsequent
molecules of ε-caprolactone are added to the Eu3+ complex via a coordination–insertion
process.12
Scheme 2.2 Proposed mechanism of polymerization of ε-caprolactone.12 Ind is the indenyl
ligand. Adapted with permission from S. Zhou, S. Wang, E. Sheng, L. Zhang, Z. Yu, X.
Xi, G. Chen, W. Luo, Y. Li. Eur. J. Inorg. Chem. 2007, 1519–1528. Copyright 2007 John
Wiley and Sons.

Because the role of the ligands on the polymerization of MMA and ε-caprolactone has
yet to be elucidated, several Eu2+ complexes {η5:η1-[1-(CH3)3Si-3-(C5H9OCH2)C9H5]}2Eu,
2.80;81 (η5:η1-C5H9OCH2C13H8)2Eu, 2.81;82 and (η5:η1-C5H10NCH2CH2C13H8)2Eu, 2.82,82
containing functionalized indenyl and fluorenyl ligands were investigated in terms of their
activity towards MMA and ε-caprolactone polymerization. The silyl substituent in the
indenyl ligands in complex 2.80 is likely a key factor in the two polymerization
processes.81 Without the silyl substituent in 2.80, no activity was observed for any reaction
condition.81 However, high activity was observed for 2.80 for both MMA and ε-
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caprolactone polymerizations. The effect of the ligand is also evident in the case of
complexes 2.81 and 2.82. Complex 2.81 with N-piperidineethyl functionalized fluorenyl
ligands has higher activity in ε-caprolactone polymerization than complex 2.81 with
tetrahydro-2H-pyranyl ligands under the same reaction conditions. However, this ligand
effect was not observed on the polymerization of MMA.
In general, Eu2+-containing complexes using fluorenyl ligands are more effective as
catalysts for both MMA and ε-caprolactone polymerizations than indenyl ligands with
similar

substituents.

While

Eu2+-containing

complexes

2.64–2.82

initiate

the

polymerization of MMA or ε-caprolactone, it would be useful to investigate the
mechanistic role of the different ligands in initiation. Also, exploration of a broader ligand
system would enable an in depth understanding of how to better control the properties of
the synthesized polymers. Although a Eu2+ complex has been used in the
cyclotrimerization of isocyanates, the scope of the ligands used is still limited. 83 These
ligand-centered studies would expand our understanding of the reduction chemistry of Eu2+
and its application to synthetic and polymer chemistry.
2.3.3 Luminescent Complexes
Aside from the rich reduction properties of Eu2+, this ion produces complexes that are
luminescent both in solution and in the solid state. Current research efforts are directed
towards developing Eu2+-containing complexes that have high luminescence efficiency.
The luminescence of uncomplexed Eu2+ and Eu3+ in protic solvents is quenched by O–
H oscillators of coordinated solvent molecules.84 Thus, macrocyclic ligands including
crown ethers and cryptands are used to encapsulate Eu2+, protecting this ion from
luminescence quenching by solvent molecules. The luminescence properties of Eu2+containing crown ethers, azacrown ethers, cryptands, and polymers were reviewed by
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Adachi and coworkers in 1998.6 Since then, efforts have focused on developing
luminescent complexes with high quantum yields by introducing functional groups into
macrocyclic ethers or by using other ligands that better encapsulate Eu2+.85–88 There is also
a growing interest in the comparison of spectroscopic properties of Eu2+ in the solid state
to Eu2+-containing complexes in solution.
A variety of functional groups have been used to study the contribution of antenna
effects and conjugated π systems on the luminescence efficiency of Eu2+-containing
complexes.86–87 Pyridine groups, known for exhibiting an antenna effect in Eu3+-containing
complexes, were introduced into 18-crown-6. When bis-pyridino-18-crown-6 was
complexed with Eu2+, the emission of the complex in the solid state was quenched at room
temperature, and only a weak emission at 430 nm was observed at 77 K, which is typical
for Eu2+-containing crown ethers.86 This quenching is likely due to the energy transfer
from the excited state quasi-5d energy level of Eu2+ to the π* levels of pyridine, and this
quenching is not observed when unfunctionalized 18-crown-6, 2.83, was used.86 However,
a blue luminescence was observed when benzo-15-crown-5, 2.84, and benzo-18-crown-6,
85, were used as ligands.54,87 The Eu2+-containing complex with benzo-15-crown-5 is
characterized by a Eu2+ metal center that is sandwiched by two benzo-15-crown-5
ligands.86 In the solid state, Eu2+–2.85 shows an emission peak that is similar to what is
observed in methanol at room temperature. This observation is also true for Eu2+containing 15-crown-5, Eu–2.86. These observations suggest that similar structures exist in
the solid state and in solution.88 The mean lifetime of the excited state of Eu2+–2.84 at
room temperature is 0.65 µs in the solid state and 0.14 µs in methanol (Table 2.1).87 This
difference in excited state lifetime is likely due to the additional relaxation processes
caused by the methanolic O–H oscillators.87 Furthermore, a phenyl moiety in the crown
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ether might contribute to a reduction in the lifetime because this moiety could rigidify the
crown ether and lead to structural changes making Eu2+ more exposed to luminescence
quenchers relative to unmodified crown ethers.6 Also, the cavity size of the crown ether
affects the luminescence lifetime of the excited state. Among the three crown ethers
studied, the cavity size of 2.86 is most efficient at reducing the number of coordinating
anions or solvent molecules that decrease luminescence lifetime.88
Table 2.1 Luminescence properties of Eu2+-containing complexes in methanol solution
and in the solid state (room temperature and 77 K).6,54,87,88
Complex

Eu2+–2.83

Maximum emission

Maximum emission

Luminescence

Luminescence

band, nm (solid)

band, nm

lifetime, µs

lifetime, µs

(methanol)

(solid)

(methanol)

ND (RT)

ND

411.5 (77 K)
Eu2+–2.84

422 (RT)

425 (RT)

417

433 (RT)

0.65 (RT)

0.14

0.59 (77 K)
447

430 (77 K)
Eu2+–2.86

ND

ND

427 (77 K)
Eu2+–2.85

ND

8.34 (RT)

0.028

8.01 (77 K)
432

417 (77 K)

0.922 (RT)

0.800

0.745 (77 K)

Legend: RT is room temperature, ND is no data available
In general, macrocylic ligands with cavity sizes that closely match the ionic radius of
Eu2+ are the best ligands to insulate Eu2+ from solvent-based luminescence quenchers.
Rigidifying ligands by adding phenyl groups and the addition of substituents like pyridine,
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leads to a decrease in luminescence emission. These factors should be taken into
consideration when designing Eu2+-based luminescent materials.
2.3.4 MRI Contrast Agents
In addition to the reducing and luminescence properties of Eu2+, the magnetic
properties of this ion are important in the development of Eu2+-based contrast agents for
magnetic resonance imaging (MRI). In the last two decades, research on the properties of
Eu2+ that are relevant to MRI has been reported. A fast water-exchange rate and an
isoelectronic ground state to Gd3+ are properties that make Eu2+ an excellent candidate for
use as a contrast agent for MRI.89 This area started when Merbach and coworkers reported
the fast water-exchange rate of the Eu2+ aqua ion that is in the order of 109 s–1. After
detailed mechanistic studies on the water exchange of the Eu2+ aqua ion,90 investigations of
the

nuclear

and

electronic

relaxation

processes

of

Eu2+

chelated

by

polyaminopolycarboxylates, commonly used with Gd3+, were performed.91 When chelated
to diethylenetriamine pentaacetate (DTPA), Eu2+ has a water-exchange rate that is three
orders of magnitude faster than the clinically approved contrast agent [GdDTPA] 2–, 2.87,
(Figure 2.9).91 In addition to water-exchange rate, other molecular parameters including
rotational correlation time and electronic spin relaxation time are important factors that
influence the efficiency of contrast agents, known as relaxivity. For example, despite the
fast water-exchange of [EuDTPA]3–, 2.88, the reported relaxivity of 2.88 at 20 MHz is
20% lower than that of 2.87 because relaxivity is influenced by fast rotation and by fast
electronic spin relaxation.91 The same observation was implicated for the higher relaxivity
of

Eu2+-containing

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate

[EuDOTA]2–

(4.74 mM–1s–1) than [EuDTPA]3– (3.49 mM–1s–1) at 20 MHz and 298 K.92 Results with
other Eu2+-containing complexes indicate that the unfavorable fast electronic spin
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relaxation rate is not observed with all Eu2+ complexes.91,93 Tóth and coworkers reported
that the electron paramagnetic resonance line widths of 2.10, are narrower by a factor of 8–
10 compared to 2.88, indicating a slower electronic spin relaxation of Eu2+ in cryptate 2.10
relative to 2.88.94 Consequently, the observed electronic spin relaxation for Eu2+containing cryptates does not limit relaxivity. In addition to slow electronic spin relaxation,
this Eu2+-containing cryptate has a fast water-exchange rate (108 s–1) and contains two
inner-sphere water molecules in a ten-coordinate complex.94 These properties are
promising because they present an opportunity to develop Eu2+-containing cryptates as
effective contrast agents for MRI. A review of the similarities and differences in terms of
these molecular parameters for several Eu2+- and Gd3+-containing complexes and their
implications to research on MRI contrast agents was written by Merbach and coworkers in
2001.93

Figure 2.9 Structures of complexes 2.87 and 2.88.
While Eu2+ has properties that make it a candidate for use as a contrast agent for MRI,
its propensity to oxidize prevents in vivo applications.57 It was demonstrated in the work of
Allen and coworkers that Eu2+ can be oxidatively stabilized using coordination chemistry
principles, including hard–soft acid–base theory, to the extent that it is more oxidatively
stable than Fe2+ in hemoglobin.57 These studies raised the possibility of using Eu2+containing cryptates for in vivo applications.
In addition to using modified cryptands as ligands to stabilize Eu2+, I investigated the
relaxivity of several Eu2+-containing cryptates 2.10–2.11 at different field strengths (1.4, 3,
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7, 9.4, and 11.7 T).25,58 These cryptates showed higher relaxivity at higher fields (7 and 9.4
T) relative to lower fields (1.4 and 3 T) unlike common Gd3+-containing contrast
agents.25,58 While high relaxivity is a requirement for effective contrast agents, other
properties including kinetic stability need to be considered for utility in vivo. I
demonstrated that Eu2+-containing cryptates 2.10 and 2.11 are stable to transmetallation in
the presence of endogenous ions such as Ca2+, Mg2+, and Zn2+,25 and the Allen group is
currently investigating the thermodynamic stability and toxicity of several other Eu 2+containing cryptates.
2.4 Conclusions
The rapid increase in the number of Eu2+-containing complexes reported in the past
few decades has paved the way to making these complexes commonplace in coordination
chemistry. New information regarding the stability and utility of Eu2+-containing
complexes using a variety of ligands has opened new frontiers in lanthanide chemistry.
Careful control of ligand properties produces Eu2+-containing complexes that are useful in
synthetic, materials, and medicinal applications.
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Chapter Three
Eu2+-Containing Cryptates as Contrast Agents for Ultra-High Field Strength MRI
Portions of this chapter were reprinted or adapted with permission from:
(1) Garcia, J.; Neelavalli, J.; Haacke, E. Mark; Allen, M. J. EuII-containing cryptates as
contrast agents for ultra-high field strength magnetic resonance imaging. Chem. Commun.
2011, 47, 12858–12860. Reproduced by permission of The Royal Society of Chemistry.
Link: http://pubs.rsc.org/en/Content/ArticleLanding/2011/CC/C1CC15219J
(2) Garcia, J.; Kuda-Wedagedara, A. N. W.; Allen, M. J. Physical Properties of Eu2+Containing Cryptates as Contrast Agents for Ultrahigh-Field Magnetic Resonance Imaging
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3.1 Introduction
Contrast-agent-enhanced magnetic resonance imaging (MRI) is a widely used,
noninvasive imaging technique for clinical and preclinical research as well as diagnostic
medicine. Most clinical imaging is performed at high field strengths (1.5 or 3 T); however,
a shift to ultra-high field strength MRI (≥7 T) is desirable because of the increased signalto-noise ratio, spatial resolution, and shorter acquisition times enabled at these fields,
which offer the potential to lead to early diagnoses of diseases and more accurate
imaging in vivo.1–4 Consequently, preclinical research relies heavily on ultra-high field
strengths. A major limitation is that common T1-reducing (positive) contrast agents at
lower field strengths, such as GdIII-containing complexes, become inefficient at ultra-high
field strengths.2,5 Multiple parameters—including the water-exchange rate, the number of
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inner-sphere water molecules, the rotational correlation time, and the relaxation times of
the electron spins of GdIII—are in a complex interplay that is crucial to increasing
relaxivity, r1, which is a measure of contrast-enhancing ability of a contrast agent.2–4 An
alternative to GdIII is EuII, which is isoelectronic with GdIII but has a faster water-exchange
rate due to its lower charge density. However, until recently, research on Eu II chemistry in
aqueous solution was limited because of its tendency to oxidize to Eu III.6–8 Modified
[2.2.2]cryptands were used to increase the oxidative stability of EuII,6 and here, the
molecular properties and imaging profiles of a series of EuII-containing [2.2.2]cryptates
(3.1–3.3 in Figure 3.1) that are, to the best of my knowledge, among a few reported
contrast agents, and the first lanthanide-based contrast agents, that are more effective at
ultra-high field strengths than at lower fields were reported.9

Figure 3.1

Structures

of GdDOTA (DOTA = 1,4,7,10-tetraazacyclododecane-

N,N’,N’’,N’’’-tetraacetate) and EuII-containing cryptates 3.1–3.3. Coordinated water
molecules have been omitted for clarity.
I hypothesized that EuII-containing [2.2.2]cryptates in aqueous solution could be
used as the basis for efficient positive contrast agents for ultra-high field strength MRI
because EuII and GdIII are isoelectronic but differ in other molecular parameters that
influence relaxivity. This hypothesis is supported by studies of EuII-containing complexes:
for example, EuII-containing [2.2.2]cryptate, 3.1, has been reported to have a fast water-
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exchange rate.8 The water-exchange rate of 3.1 is 3 × 108 s−1, which is faster than most
GdIII-based complexes and is very close to the optimal value (~108 s−1 at 7 T) for
developing efficient MRI contrast agents at ultra-high fields.2,8 Attempts to increase
the water-exchange rate of GdIII-containing complexes have been made by altering the
coordination number of ligands for GdIII or by increasing steric bulk at the site where
inner-sphere water binds.10 However, because of the complicated interplay between waterexchange rate and other parameters that affect relaxivity, there is a need to simultaneously
optimize all factors to increase the efficacy of contrast agents. In addition to its
optimal water-exchange rate, 3.1 has two inner-sphere water molecules in a ten-coordinate
complex, which should enable higher relaxivity than an equivalent complex with only one
inner-sphere water molecule according to Solomon–Bloembergen–Morgan (SBM) theory.
These favorable molecular properties prompted me to hypothesize that EuII-containing
cryptates would be candidates for contrast agents at ultra-high field MRI.
To test my hypothesis, I investigated the imaging (longitudinal relaxivity, r1, at 3
and 7 T) and physical (water-exchange rate, electron-spin relaxation rate, and number of
inner-sphere water molecules) properties of a series of EuII-containing [2.2.2]cryptates
(Figure 3.1). Cryptands of 3.1 and 3.2 are commercially available, and I synthesized
cryptate 3.3 (Scheme 3.1).
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Scheme 3.1 Synthesis of biphenyl-based Eu2+-containing cryptate.

3.2 Imaging Properties of Eu2+-Containing Cryptates
3.2.1 Influence of Magnetic Field on Relaxivity
Relaxivity was determined using multiple flip angles in gradient echo imaging
experiments performed between 19 and 20 °C at 3 and 7 T (Table 3.1) and inversion
recovery experiments at either 20 or 37 °C at 1.4 T.11 At all of these field strengths, EuIIcontaining cryptates 3.2 and 3.3 displayed higher r1 than clinically approved GdDOTA (up
to 46, 71, and 92 higher at 1.4, 3, and 7 T, respectively). Furthermore,
cryptate 3.1 displayed a higher relaxivity than GdDOTA at 7 T. I found that the r1 values
of GdDOTA were not different at 3 and 7 T (Student t test). This result was expected based
on what is known about fast rotating GdIII-containing complexes.3 However, EuIIcontaining complexes 3.1–3.3 showed an increase in r1 values at 7 relative to 3 T.12
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Additionally, the r1 values of cryptates 3.1–3.3 increased as a function of molecular weight
at all field strengths. These cryptates are two of a few examples of paramagnetic materials
that demonstrate an increase in relaxivity at ultrahigh field strengths relative to lower field
strengths.13
Table 3.1 r1 values of GdDOTA and EuII-containing cryptates
r1 at 1.4 T

r1 at 3 T

r1 at 7 T

(mM–1s–1)

(mM–1s–1)

(mM–1s–1)

T = 37 °C

T = 19.8 °C

T = 19 °C

GdDOTA

3.00 ± 0.06

3.69 ± 0.06

3.73 ± 0.01

3.1

2.09 ± 0.02

3.94 ± 0.12

5.01 ± 0.03

3.2

3.67 ± 0.09

4.84 ± 0.08

6.47 ± 0.17

3.3

4.39 ± 0.10

6.31 ± 0.07

7.17 ± 0.04

All complexes were in phosphate buffered saline (PBS, pH = 7.4). Results are reported as
mean ± standard error.
To establish a more complete understanding of the behavior of the efficacy of these
cryptates as a function of field strength, we measured the relaxivity of 3.1 and 3.2 at field
strengths of 1.4, 3, 7, 9.4, and 11.7 T. These measurements allowed us to compare the
efficiency of Eu2+-containing complexes at clinically relevant field strengths (1.4 and 3 T)
with that at higher field strengths, which are commonly used in preclinical research (> 3
T). Because relaxivity is dependent on temperature,12b we compared field strengths at the
same temperature.
On comparing the efficacy of Eu2+-containing cryptates at field strengths of 3, 7,
9.4, and 11.7 T (20 °C, pH = 7.4), the relaxivity of 3.2 is higher than that of 3.1 at all field
strengths (Figure 3.2). This difference in relaxivity is likely due to the difference in
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rotational correlation rate, which is the rate at which these molecules tumble in solution.
This rate is proportional to the molecular weight for structurally similar compounds.14 The
relaxivity of 3.1 increases from 3 to 7 T followed by a decrease above 9.4 T and that of Eu3.2 shows an increase in relaxivity from 3 to 7 T followed by a decrease above 7 T. This
“bump” could be similar to the bump with a maximum value between 7 and 9.4 T observed
at lower field strengths in the NMR dispersion plots of slowly rotating Gd3+-based contrast
agents.2 An attempt to explain this increase in relaxivity at higher fields was made using a
simulation of the Solomon–Bloembergen–Morgan (SBM) equations. Although the
relaxivity values from this simulation matched the trend observed for GdDOTA, they did
not fit the experimental data for Eu2+-containing complexes. The results of this simulation
indicate that SBM theory alone cannot explain our observations.

Relaxivity (mM–1s–1)

7

4.5

2
2

4.5

7
9.5
Field Strength (T)

12

Figure 3.2 Proton longitudinal relaxivity (T = 20 °C, pH = 7.4) of GdDOTA (○) and Eu2+containing cryptates 3.1 (◊) and 3.2 (□) as a function of magnetic field strength. Error bars
represent standard error of the mean.
At a higher temperature (T = 37 °C, pH = 7.4, Figure 3.3), 3.1 displays an increase
in relaxivity from 1.4 to 7 T and a decrease above 9.4 T. However, at 37 °C, the relaxivity
of 3.2 at 1.4 and 9.4 T is the same. At all field strengths and temperatures measured
(except 1.4 T), 3.1and 3.2 have higher relaxivities than GdDOTA. To further explain the
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influence of temperature on the relaxivity of 3.1 and 3.2, I measured relaxivity as a
function of temperature at constant field strength.

Relaxivity (mM–1s–1)
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Field Strength (T)
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Figure 3.3 Proton longitudinal relaxivity (T = 37 °C, pH = 7.4) of GdDOTA (○) and Eu2+containing cryptates 3.1 (◊) and 3.2 (□) as a function of magnetic field strength. Error bars
represent standard error of the mean.
3.2.2 Influence of Temperature on Relaxivity
Temperature can have a dramatic influence on the relaxivity of contrast agents. To
explore the temperature dependence of the relaxivity of 3.1 and 3.2, I measured the
relaxivity at 15, 20, 30, 37, and 50 °C at 9.4 and 11.7 T at pH = 7.4 (Figures 3.4 and 3.5).
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Figure 3.4 Proton longitudinal relaxivity (9.4 T and pH = 7.4) of Eu2+-containing cryptates
3.1 (□) and 3.2 (○) as a function of temperature. Error bars represent standard error of the
mean.
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Figure 3.5 Proton longitudinal relaxivity (11.7 T, pH = 7.4) of Eu2+-containing cryptates
3.1 (□) and 3.2 (○) as a function of temperature. Error bars represent standard error of the
mean.
Another temperature-dependent parameter that contributes to relaxivity is waterexchange rate, which is important when it approaches the magnitude of the relaxation rate
of the bound water. When this happens, the plot of relaxivity versus temperature should
show a plateau or a positive slope in the low temperature region. This case was not
observed for either 3.1 or 3.2, implying that the water-exchange rates of 3.1 and 3.2 are
fast enough to not limit relaxivity even at low temperatures. This conclusion is supported
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by the results of variable temperature

17

O NMR studies, which revealed that crypates 3.1

and 3.2 have water-exchange rates of 3.3 × 108 s–1 and 0.85 × 108 s–1, respectively. In
general, the variation in the relaxivities of these cryptates with temperature is likely due to
the changes in the rotational correlation rate of the complexes as temperature changes,
similar to what is observed with Gd3+-containing complexes.
3.2.3 Influence of pH on Relaxivity
The effect of pH on the relaxivity of Eu2+-containing cryptates as contrast agents was
examined as a gauge of their performance in vivo and to explore the potential of these
complexes to behave as pH responsive agents (Figure 3.6).
At 7 T and 19 °C, the relaxivity of 3.1 did not change significantly at any of the pH
values measured from 3 to 10 (p = 0.01). The relaxivity of 3.2 exhibited the same behavior.
These observations are expected for complexes that do not have functional groups that are
sensitive to pH changes. Also, at 1.4 T and 37 °C, the relaxivity of 3.1 is independent of
pH value (p = 0.01). However, the relaxivity of 3.2 remained constant below pH 7.4, but
between pH values of 7.4 and 8, the relaxivity of 3.2 decreased by 22% (from 3.67 ± 0.09
to 2.86 ± 0.02 mM–1s–1) and remained constant above pH 8. In summary, the experiments
at different pH values for 3.1 and 3.2 under two different sets of conditions (7 T at 19 °C
and 1.4 T at 37 °C) indicate that the relaxivity of these cryptates is not influenced by pH
over a physiologically relevant range.
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Figure 3.6 Longitudinal relaxivity at 1.4 T at 37 °C (3.1 (■) and 3.2 (●)) and 7 T at 19 °C
(3.1 (□) and 3.2 (○)) as a function of pH. Error bars represent standard error of the mean.
3.2.4 Phantom Imaging Experiments
To demonstrate the consequence of having higher relaxivity, I obtained phantom
images (images of solutions) of GdDOTA and EuII-containing complexes 3.1–3.3 using T1weighted imaging at 7 T (Figure 3.7). The MR images of EuII cryptates 3.1–3.3 showed
higher signal intensity relative to PBS. This observation is indicative that EuII cryptates are
effective at influencing the relaxation of water protons in solution. The signal intensities of
the EuII complexes are different from each other (Student t test) with 3.3 giving rise to the
highest signal intensity. The 1/T1 values were between 29 and 89% higher for
cryptates 3.1–3.3 relative to GdDOTA. An increase in 1/T1 corresponds to higher signal
intensity and, therefore, is advantageous for imaging. These imaging experiments
demonstrate that cryptates 3.1–3.3 are effective contrast agents at ultra-high field strengths.
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Figure 3.7 (a) T1-weighted MR images of solutions of PBS, GdDOTA (1.0 mM in PBS),
and 3.1–3.3 (1.0 mM in PBS) at 7 T. The diameter of the tubes that were used for imaging
was 6 mm. Imaging parameters were TR = 21 ms; TE = 3.26 ms; and resolution = 0.27 ×
0.27 × 2 mm3. (b) Comparison of 1/T1 values of the samples from (a) at 7 T. Error bars
represent standard error of the mean.
3.3 Physical Properties of Eu2+-Containing Cryptates
3.3.1 Variable-Temperature 17O NMR Spectroscopy
To understand the observations of r1 values, I used variable temperature 17O NMR
spectroscopy to determine the molecular parameters expected to influence relaxivity
(Table 3.2): the residence lifetime of bound water molecules, τm298, where water-exchange
rate, kex298, is equal to 1/τm298; the longitudinal electronic relaxation time, T1e298; and the
number of inner-sphere water molecules, q. To attain the highest relaxivity at ultra-high
field strengths, water-exchange rate must be ~108 s−1.2 The water-exchange rates of the
EuII complexes are 6–94 times faster than GdDOTA and, consequently, are closer to being
optimal at ultra-high field strengths as described by SBM theory. However, our
observed water-exchange rate does not limit the relaxation enhancement for fast rotating
complexes even at ultra-high fields. As seen from the data in Tables 3.1 and 3.2, r1 values
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were

larger

for

cryptates 3.2 and 3.3 relative

to 3.1 despite 3.2 and 3.3 having

slower water-exchange rates than 3.1. The differences in water-exchange rates among 3.1,
3.2, and 3.3 could be attributed to the flexibility of the cryptates because having a flexible
structure may lead to changes in steric bulk at the water-binding site thereby affecting
water-exchange rate. The relaxivity differences among cyptates 3.1–3.3 are likely due to
differences in molecular weight because increases in molecular weight correspond to
decreases in rotational correlation rates for structurally similar monomeric complexes.13
Table 3.2 Relaxivity parameters (based on 17O NMR and EPR data) and molecular
weights of GdDOTA and cryptates 3.1–3.3.

a

GdDOTA

3.1

3.2

3.3

τm298 (ns)

287 ± 10

3.0 ± 0.4

11.7 ± 0.3

48 ± 4

kex298 (108 s–1)

0.035

3.3

0.85

0.21

q

1

2

2

2

T1e (ns)

29

120

41

1100

g

1.9847

1.9774

1.9790

1.9786

1/T2e (109 s–1)

0.91

2.7

3.4

4.0

τR (ns)a

–

19.6

2.72

2.27

MW (Da)

591

564

657

731

See Section 3.7 of this chapter for the method of estimating τR.

SBM theory also describes the dependence of relaxivity on the electron spin relaxation,
which we investigated with 17O NMR studies. Data acquired from variable temperature 17O
NMR experiments were refitted using 63 unique values of T1e298 in the range of 10−8–
10−3 s, and the T1e298 values that were associated with the best correlation coefficient are
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reported in Table 3.2. The electron-spin relaxation rates of the EuII ion in cryptates 3.1–
3.3 were in the range of 106–107 s−1 and were not limiting as evidenced by the change in
relaxivity with molecular weight. The differences in the obtained electronic relaxation rates
among 3.1, 3.2, and 3.3 could be attributed to the symmetry differences among the
cryptates. However, the influence of structural factors to correlation times that describe
electronic spin relaxation is not yet fully understood.15 Another key parameter in
increasing relaxivity at ultra-high fields is the number of inner-sphere water molecules.
EuII cryptates have two inner-sphere water molecules, which corresponds to higher
efficiency

of

a

contrast

agent

relative

to

complexes

with

fewer

inner-

sphere water molecules. In general, the superiority of the EuII cryptates over GdDOTA in
enhancing relaxivity at ultra-high field strengths is likely due to a combination of factors. I
have determined kex298, q, and T1e298 for cryptates 3.1–3.3 in an attempt to explain the
molecular basis for our observations; however, the results cannot be satisfactorily
interpreted using SBM theory.
3.3.2 Electron Paramagnetic Resonance (EPR) Spectroscopy
In addition to relaxivity and 17O NMR experiments, I also performed EPR experiments
to investigate the electronic properties of these cryptates that include the g factor and the
transverse electronic spin relaxation rate, 1/T2e, of the metal ion. The g factor values for all
the complexes are almost close to 2 (Table 3.2). This value is expected for complexes of
which the metal ion has an f7 electronic configuration.
The EPR peak of Eu2+ shown in Figure 3.8 at X-band is likely to be a superposition of
12 lines, which could become visible at higher frequencies (~225 GHz), as a result of
coupling of Eu2+ isotopes,

151

Eu and

153

Eu, with similar spin (I = 5/2) and natural

abundance (47.82 and 52.18%, respectively).16 The presence of a shoulder in the EPR
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profile could also be attributed to the presence of a mixture of species–a cryptate with one
inner-sphere water molecule and a species with two coordinated water molecules.
Comparing the X-band EPR profile of the unfunctionalized cryptate 3.1 to that of
GdDOTA, the peak-to-peak linewidth in the EPR plot of cryptate 3.1 is wider relative to
that of GdDOTA (Figures 3.8 and 3.9). This translates to a faster electron spin relaxation
for Eu2+ relative to Gd3+ as implied in Eq 3.1:
Eq 3.1

√

where β is the Bohr magneton constant, ΔHpp is the peak-to-peak linewidth, and h is the
Planck’s constant. Using the g factor, the transverse electron spin relaxation rate can be
calculated, and looking at the 1/T2e values on Table 3.2, these cryptates have faster
electronic spin relaxation rate (2.97–4.40 times faster) than GdDOTA.
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Figure 3.8 X band EPR spectrum of cryptate 3.1 in PBS at 77 K.

66

Intensity (a.u.)

31000

2800
-21000

3800

Field Strength (Gauss)

Figure 3.9 X band EPR spectrum of GdDOTA in PBS at 77 K.
3.4 Conclusions
This study demonstrated that EuII-based complexes 3.1–3.3 are effective contrast
agents at ultra-high field strengths likely because of the interplay of water-exchange rate,
rotational correlation rate, and the presence of two inner-sphere water molecules. To the
best of our knowledge, these complexes are among a few reported examples of contrast
agents that display increased r1 values at ultra-high field strengths relative to lower fields.
Relaxometric studies of 3.1 and 3.2 showed that the efficiencies of these cryptates were
higher at 7 and 9.4 T at 20 °C. Furthermore, the relaxivities of these complexes decreased
as the temperature increased from 15 to 50 °C, likely due to the increase in rotational
correlation rate with increasing temperature. In addition, the efficacy of 3.1 and 3.2 did not
vary significantly in the pH range of 3–10, which suggests that these complexes are
expected to display constant relaxivity in biologically relevant pH ranges. These studies
lay the foundation for the use of Eu2+-containing cryptates as contrast agents for MRI.
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3.5 Experimental Procedures
3.5.1 Materials
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB
Ultra Mk2 water purification system (ELGA). Dicholoromethane was dried using a solvent
purification system (Vacuum Atmospheres Company) and degassed under vacuum.
Triethylamine was distilled from CaH2 under an atmosphere of Ar.17 4-Allylbiphenyl was
prepared according to a published procedure.18 Ozone was generated using an apparatus
from Ozone Research and Equipment Corporation. For ozone generation, oxygen was
passed through a column of anhydrous calcium sulfate before the ozone apparatus, and the
oxygen flow rate and current were held constant at 1.0 L/min and 0.8 A, respectively. pToluenesulfonyl chloride was recrystallized prior to use.17
Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD
Chemicals).19 Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC
plates precoated with silica gel 60 F254 (250 μm layer thickness). TLC visualization was
accomplished using a UV lamp followed by charring with potassium permanganate stain
(2 g KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous NaOH, 300 mL H2O).
The following commercially available buffers were degassed and used in relaxometric
experiments: glycine/HCl (pH = 3), acetate (pH = 5), PBS (pH = 7.4), 2-amino-2(hydroxymethyl)propane-1,3-diol (TRIS) (pH = 8), and glycine/NaOH (pH = 10).
3.5.2 Characterization
1

H NMR spectra were obtained using a Varian Unity 400 (400 MHz) spectrometer, and

13

C NMR spectra were obtained using a Varian Unity 400 (101 MHz) spectrometer.

Chemical shifts are reported relative to residual solvent signals (CD3OD: 1H:  3.30, 13C: 
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49.00; CD3CN: 1H:  1.94, 13C:  118.26 and 1.30). 1H NMR data are assumed to be first
order, and the apparent multiplicity is reported as “s” = singlet, “m” = multiplet, and “brs”
= broad singlet. Italicized elements are those that are responsible for the shifts. Highresolution electrospray ionization mass spectra (HRESIMS) were obtained using an
electrospray time-of-flight high-resolution Waters Micromass LCT Premier XE mass
spectrometer.
Samples for inductively coupled plasma mass spectrometry (ICP–MS) were diluted
using aqueous 2% nitric acid. Standard solutions were prepared by serial dilution using Eu,
Gd, and Sr standards (High-Purity Standards). ICP–MS measurements were conducted on
a PE Sciex Elan 9000 ICP–MS instrument with a cross-flow nebulizer and Scott-type spray
chamber.
3.5.3 Imaging and Relaxometric Experiments
Susceptibility weighted imaging (SWI) and Volumetric Interpolated Breath Hold
Examination (VIBE) were performed at 3 (Siemens TRIO) and 7 (ClinScan) Tesla (T). The
acquisition parameters for SWI were as follows: TR = 37 ms, TE = 5.68–31.18 ms, and
resolution = 0.5 × 0.5 × 2 mm3 for 3 T; TR = 21 ms, TE = 3.26–15.44 ms, and resolution =
0.27 × 0.27 × 2 mm3 for 7 T. Multiple flip angles (5, 10, 15, 20, 25, and 30°) were used in
the SWI experiments to allow for the determination of longitudinal relaxation time, T1.20
On the other hand, the parameters used for VIBE were as follows: TR = 5 ms, TE = 1.71 ms,
and resolution = 0.27 × 0.27 × 2 mm3 for 7 T. MR images were processed using SPIN
software (SVN Revision 1751). Matlab (7.12.0.635 R2011a) was used to generate effective
transverse relaxation time, T2*, and corrected T1 maps. The T1 values from the corrected T1
maps were plotted vs the concentration of Gd or Eu in the samples to calculate longitudinal
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relaxivities, r1. The Matlab codes for T2* and T1 (with T2* correction) maps are shown in
Appendix A.
Inverse recovery experiments were performed using Bruker minispec mq (1.4 T), a
Varian Unity 400 (9.4 T) at 400 MHz, and Varian–500S (11.7 T) spectrometer using
GdDOTA, 3.1, 3.2, and 3.3 as samples, which were dissolved in degassed phosphate
buffered saline (PBS) solutions (pH = 7.4). All the T1 measurements were made at 37 °C.
The relaxivity of the complexes were calculated from the slopes of the linear plots of 1/T1
versus concentration.
Longitudinal relaxation times, T1, were also measured using inverse recovery methods
with a Varian Unity 400 (9.4 T) at 400 MHz and 15, 20, 30, 37, and 50 °C, and a Varian
500S instrument (11.7 T) at 500 MHz and 15, 20, 30, 37, and 50 °C.
Variable-temperature 17O NMR measurements of degassed solutions of GdDOTA (20
mM); 3.1 (5.0 mM); 3.2 (0.50 mM); 3.3 (0.42 mM), and their SrII analogues of 3.1 (5.0
mM), 3.2 (0.50 mM), and 3.3 (0.42 mM) in phosphate buffered saline (PBS, pH = 7.4) as
well as acidified water (HClO4, pH 3.4) were obtained on a Varian–500S (11.7 T)
spectrometer. 17O-enriched water (10% H217O, Cambridge Isotope Laboratories, Inc.) was
added to samples to yield 1%

17

O enrichment. Transverse and longitudinal

17

O relaxation

rates and chemical shifts were measured at 15, 20, 30, 40, 50, 60, and 70 °C. The Sr II
analogues of 3.1, 3.2, 3.3, and the acidified water were used as diamagnetic references.
A/ħ, q, and ΔE were fixed to –3.8 × 10–6 rad/s, 2, and 2.5 × 10–11 J/mol, respectively, for
EuII-containing cryptates. Data acquired from variable-temperature 17O NMR experiments
were fitted using sixty unique values of T1e298 in the range of 10–8–10–3 s, and the T1e298
values that were associated with the best correlation coefficients were reported. The leastsquares fits of the 17O NMR relaxation data were calculated using Origin software (8.0951

70
B951) following published procedures.21 The variable temperature 17O NMR data and fits
are presented in Tables 3.3–3.6 and Figures 3.8–3.11.
Table 3.3 17O NMR data for acidified water and GdDOTA.
Temperature (°C)

Linewidth (Hz)
Acidified water

GdDOTA

70

33

97

60

39

137

50

50

197

40

68

249

30

99

281

20

137

256

15

160

241

71

Figure 3.10 17O NMR fits for GdDOTA.
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Table 3.4 17O NMR data for SrII analog of 3.1 and cryptate 3.1.
Temperature (°C)

Linewidth (Hz)
Sr analog of 3.1

3.1

70

30

31

60

34

37

50

40

46

40

53

57

30

64

73

20

91

111

15

107

142

73

Figure 3.11 17O NMR fits for cryptate 3.1.
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Table 3.5 17O NMR data for SrII analog of 3.2 and cryptate 3.2.
Temperature (°C)

Linewidth (Hz)
Sr analog of 3.2

3.2

70

30

37

60

34

45

50

41

57

40

52

75

30

71

105

20

102

154

15

126

183

75

Figure 3.12 17O NMR fits for cryptate 3.2.
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Table 3.6 17O NMR data for SrII analog of 3.3 and cryptate 3.3.
Temperature (°C)

Linewidth (Hz)
Sr analog of 3.3

3.3

70

29

30

60

33

35

50

39

43

40

48

55

30

63

75

20

90

108

15

112

134

77

Figure 3.13 17O NMR fits for cryptate 3.3.
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The T1e value for each complex corresponds to the T1e that gave the best correlation
coefficient. A table is presented below that shows unique T1e values in the range 10–8 to
10–3 s and their corresponding correlation coefficient for each of the four complexes when
they were used in the fitting of the NMR data. The reported T1e values are shown in bold in
the table.
Table 3.7 T1e values for GdDOTA and cryptates 3.1–3.3 and the corresponding correlation
coefficients (R2) in the 17O NMR fits.
Correlation coefficient (R2)

T1e (s)
GdDOTA

3.1

3.2

3.3

1 × 10–8

–8.51

0.91

0.67

–1.04

2 × 10–8

0.69

0.95

0.99

–0.47

3 × 10–8

0.98

0.96

0.99

–0.11

4 × 10–8

0.70

0.96

1

0.12

5 × 10–8

0.21

0.96

0.99

0.29

6 × 10–8

–0.33

0.96

0.99

0.42

7 × 10–8

–0.87

0.96

0.99

0.51

8 × 10–8

–1.37

0.96

0.99

0.58

9 × 10–8

–1.83

0.96

0.99

0.64

1 × 10–7

–2.24

0.96

0.99

0.69

2 × 10–7

–4.79

0.97

0.99

0.88

3 × 10–7

–4.82

0.97

0.99

0.94

4 × 10–7

–4.84

0.97

0.99

0.96

5 × 10–7

–4.85

0.97

0.99

0.97
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6 × 10–7

–4.86

0.97

0.99

0.97

7 × 10–7

–4.86

0.97

0.99

0.98

8 × 10–7

–4.86

0.97

0.99

0.98

9 × 10–7

–4.86

0.97

0.99

0.98

1 × 10–6

–4.87

0.97

0.99

0.98

2 × 10–6

–4.87

0.97

0.99

0.99

3 × 10–6

–4.87

0.97

0.99

0.99

4 × 10–6

–4.87

0.97

0.99

0.99

5 × 10–6

–4.87

0.97

0.99

0.99

6 × 10–6

–4.87

0.97

0.99

0.99

7 × 10–6

–4.87

0.97

0.99

0.99

8 × 10–6

–4.87

0.97

0.99

0.99

9 × 10–6

–4.88

0.97

0.99

0.99

1 × 10–5

–4.88

0.97

0.99

0.99

2 × 10–5

–4.88

0.97

0.99

0.99

3 × 10–5

–4.88

0.97

0.99

0.99

4 × 10–5

–4.88

0.97

0.99

0.99

5 × 10–5

–4.88

0.97

0.99

0.99

6 × 10–5

–4.88

0.97

0.99

0.99

7 × 10–5

–4.88

0.97

0.99

0.99

8 × 10–5

–4.88

0.97

0.99

0.99

9 × 10–5

–4.88

0.97

0.99

0.99

1 × 10–4

–4.88

0.97

0.99

0.99
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2 × 10–4

–4.88

0.97

0.99

0.99

3 × 10–4

–4.88

0.97

0.99

0.99

4 × 10–4

–4.88

0.97

0.99

0.99

5 × 10–4

–4.88

0.97

0.99

0.99

6 × 10–4

–4.88

0.97

0.99

0.99

7 × 10–4

–4.88

0.97

0.99

0.99

8 × 10–4

–4.88

0.97

0.99

0.99

9 × 10–4

–4.88

0.97

0.99

0.99

1 × 10–3

–4.88

0.97

0.99

0.99

2 × 10–3

–4.88

0.97

0.99

0.99

3 × 10–3

–4.88

0.97

0.99

0.99

4 × 10–3

–4.88

0.97

0.99

0.99

5 × 10–3

–4.88

0.97

0.99

0.99

6 × 10–3

–4.88

0.97

0.99

0.99

7 × 10–3

–4.88

0.97

0.99

0.99

8 × 10–3

–4.88

0.97

0.99

0.99

9 × 10–3

–4.88

0.97

0.99

0.99
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.18
1.69
0.96
0.58
0.40
0.22

0.31
0.59
1.05
1.71
2.51
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.13
1.67
0.93
0.58
0.40
0.22

0.32
0.60
1.07
1.74
2.52
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.33
1.79
1.00
0.60
0.41
0.22

0.30
0.56
1.00
1.66
2.45
4.63

y = 2.9675x + 0.2136
R² = 1

4.00
2.00
0.00
0

0.5

1

1.5

Gd Concentration (mM)

1/T1 (s^-1)

(mM)

1/T1
(s–1)

4.00

y = 2.9147x + 0.2126
R² = 1

2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.8 T1 data for GdDOTA (1.4 T, Temp = 37 °C).

y = 3.1195x + 0.2163
R² = 1

4.00
2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

2.30
1.24
0.73
0.44
0.30
0.22

0.43
0.81
1.37
2.26
3.38
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

2.31
1.27
0.65
0.47
0.29
0.22

0.43
0.79
1.54
2.13
3.39
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

2.31
1.27
0.65
0.47
0.29
0.22

0.43
0.79
1.54
2.13
3.39
4.63

y = 2.1095x + 0.1897
R² = 0.9995

3
2
1
0
0

0.5

1

1.5

Eu Concentration (mM)

1/T1 (s^-1)

(mM)

y = 2.1239x + 0.1815
R² = 0.9979

3
2
1
0
0

0.5

1

1.5

Eu Concentration (mM)

1/T1 (S-1)

Concn

1/T1 (s^-1)

Table 3.9 T1 data for Cryptate 3.1 (1.4 T, Temp = 37 °C).

y = 2.0506x + 0.1829
R² = 0.9984

3
2
1
0
0

0.5

1

Eu Concentration (mM)

1.5

82
Table 3.10 T1 data for Cryptate 3.2 (1.4 T, Temp = 37 °C).

1
0.5
0.25
0.125
0.0625
0

3.97
2.13
1.14
0.69
0.45
0.22

0.25
0.47
0.88
1.46
2.21
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.96
2.00
1.15
0.68
0.36
0.22

0.25
0.50
0.87
1.48
2.76
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.69
2.02
1.11
0.66
0.44
0.22

0.27
0.50
0.90
1.51
2.30
4.63

6
1/T1 (s^-1)

T1
(s)

y = 3.7665x + 0.2155
R² = 0.9999

4
2
0
0

0.5

1

1.5

Eu Concentration (mM)

(s^-1)
1/T1
1/T1(s^-1)

1/T1
(s–1)

(mM)

y = 2.9675x + 0.2136
4.00
6
y = 3.7594x
R²+=0.1809
1
R² = 0.9991
4
2.00
2
0.00
0
0
0

0.5
0.5

1
1

1.5
1.5

Eu
Gd Concentration
Concentration (mM)
(mM)

1/T1 (s^-1)

Concn

y = 3.4831x + 0.2309
R² = 0.9996

4
3
2
1
0
0

0.5

1

1.5

Eu Concentration (mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.57
2.36
1.25
0.72
0.47
0.22

0.22
0.42
0.80
1.40
2.14
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.77
2.45
1.33
0.75
0.47
0.22

0.21
0.41
0.75
1.33
2.12
4.63

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.41
2.30
1.23
0.70
0.44
0.22

0.23
0.43
0.81
1.43
2.27
4.63

y = 4.3686x + 0.186
R² = 0.9998

6
4
2
0
0

0.5

1

1.5

Eu Concentration (mM)

1/T1 (s^-1)

(mM)

6

y = 4.5666x + 0.1898
R² = 0.9999

4
2
0
0

0.5

1

1.5

Eu Concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.11 T1 data for Cryptate 3.3 (1.4 T, Temp = 37 °C).

6

y = 4.2234x + 0.1867
R² = 0.9999

4
2
0
0

0.5

1

Eu Concentration (mM)

1.5

83
Table 3.12 T1 data for GdDOTA (3 T, Temp = 19.8 °C).

1
0.5
0.25
0.125
0.0625
0

3.86
1.88
0.95
0.53
0.45
0.23

0.26
0.53
1.06
1.90
2.24
4.36

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.98
1.90
1.07
0.58
0.38
0.21

0.25
0.53
0.93
1.71
2.65
4.78

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.97
1.93
1.05
0.63
0.34
0.22

0.25
0.52
0.95
1.58
2.91
4.62

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.73
1.96
1.02
0.60
0.36
0.24

0.27
0.51
0.98
1.66
2.78
4.19

y = 3.6585x + 0.1338
R² = 0.9955

6.00
1/T1 (s^-1)

T1
(s)

4.00
2.00
0.00
0

0.5

1

1.5

Gd Concentration (mM)

1/T1
(s^-1)
1/T1(s^-1)

1/T1
(s–1)

y = 2.9675x + 0.2136
y = 3.7873x
R² = +1 0.1323
R² = 0.9975

4.00
6.00
2.00
4.00
2.00
0.00
0.00 0
0

0.5
0.5

1
1

1.5
1.5

GdConcentration
concentraton (mM)
(mM)
Gd
6.00
1/T1 (s^-1)

(mM)

y = 3.776x + 0.1366
R² = 0.9979

4.00
2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

(s^-1)
1/T1
1/T1 (s^-1)

Concn

5.00
4.00
4.00
3.00
3.00
2.00
2.00
1.00
1.00
0.00

yy == 3.5511x
0.1733
3.776x ++0.1366
R² == 0.9979
0.9992
R²

0

0.5

1

Gd concentration (mM)

1.5
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

3.88
2.11
1.10
0.64
0.47
0.23

0.26
0.48
0.91
1.55
2.11
4.36

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.44
2.17
1.18
0.65
0.44
0.21

0.23
0.46
0.85
1.55
2.27
4.78

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.10
2.13
1.07
0.66
0.48
0.22

0.24
0.47
0.93
1.51
2.09
4.62

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.17
2.16
1.08
0.63
0.46
0.24

0.24
0.46
0.92
1.60
2.18
4.19

y = 3.6688x + 0.221
R² = 0.9994

6.00
4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

1/T1
(s–1)

6.00

y = 4.2435x + 0.1438
R² = 0.9985

4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

(mM)

6.00

y = 3.8898x + 0.1868
R² = 0.9989

4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.13 T1 data for Cryptate 3.1 (3 T, Temp = 19.8 °C).

y = 3.9709x + 0.1742
R² = 0.9987

6.00
4.00
2.00
0.00
0

0.5

1

Eu concentration (mM)

1.5
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.29
2.34
1.26
0.74
0.48
0.23

0.19
0.43
0.79
1.35
2.07
4.36

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.03
2.46
1.33
0.72
0.45
0.21

0.20
0.41
0.75
1.38
2.22
4.78

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.98
2.56
1.23
0.73
0.41
0.22

0.20
0.39
0.81
1.38
2.42
4.62

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.83
2.48
1.23
0.68
0.48
0.24

0.21
0.40
0.82
1.48
2.08
4.19

y = 5.0371x + 0.0987
R² = 0.9927

6.00
4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

y = 4.832x + 0.1405
R² = 0.999

6.00
1/T1 (s^-1)

1/T1
(s–1)

4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

5.00
4.8284x
+0.1733
0.127
6.00 yyy===3.5511x
4.00
3.776x
++0.1366
R²
0.9992
R²===0.9979
0.9988
4.00
R²
3.00
4.00
3.00
2.00
2.00
2.00
1.00
0.00
0.5
1
0.00
0.00 0
0
11 (mM)
Eu0.5
concentration
0
0.5
Gd
Gd concentration
concentration (mM)
(mM)

(s^-1)
1/T1
1/T1(s^-1)
1/T1 (s^-1)

(mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.14 T1 data for Cryptate 3.2 (3 T, Temp = 19.8 °C).

6.00

1.5
1.5
1.5

y = 4.6489x + 0.1534
R² = 0.9986

4.00
2.00
0.00
0

0.5

1

Eu concentration (mM)

1.5

86
Table 3.15 T1 data for Cryptate 3.3 (3 T, Temp = 19.8 °C).

1
0.5
0.25
0.125
0.0625
0

6.58
3.05
1.69
0.86
0.60
0.23

0.15
0.33
0.59
1.16
1.68
4.36

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

6.62
3.07
1.62
0.85
0.54
0.21

0.15
0.33
0.62
1.17
1.85
4.78

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

6.29
3.24
1.83
0.83
0.53
0.22

0.16
0.31
0.55
1.20
1.90
4.62

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

6.58
3.06
1.52
0.83
0.52
0.24

0.15
0.33
0.66
1.20
1.93
4.19

10.00

1/T1 (s^-1)

T1
(s)

y = 6.3294x + 0.1245
R² = 0.9967

5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

1/T1
(s–1)

y = 6.4163x + 0.0797
R² = 0.9969

10.00
5.00
0.00
0

(s^-1)
1/T1
1/T1(s^-1)

(mM)

1/T1 (s^-1)

Concn

0.5
1
1.5
Eu concentration (mM)

y = 3.5511x
0.1733
5.00
4.00
3.776x ++0.1366
10.00 yy =
= 6.1245x
+ 0.1777
R² == 0.9979
0.9992
4.00
R²
3.00
R² = 0.9989
3.00
5.00
2.00
2.00
0.00
1.00
0.5
1
0.00
0.00 0
0
0.5
11(mM)
Eu concentration
0
0.5
Gd
Gd concentration
concentration (mM)
(mM)

1.5
1.5
1.5

y = 6.3816x + 0.0641
R² = 0.9962

10.00
5.00
0.00
0

0.5

1

Eu concentration (mM)

1.5
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.07
2.16
1.25
0.70
0.46
0.51

0.25
0.46
0.80
1.42
2.20
1.96

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.08
2.19
1.25
0.70
0.46
0.56

0.25
0.46
0.80
1.43
2.18
1.77

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.08
2.19
1.24
0.70
0.45
0.50

0.25
0.46
0.80
1.43
2.20
1.99

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

4.10
2.22
1.24
0.71
0.46
0.54

0.24
0.45
0.81
1.42
2.17
1.86

6.00

y = 3.7106x + 0.3254
R² = 0.9945

4.00
2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

y = 3.7101x + 0.3426
R² = 0.9923

6.00
1/T1 (s^-1)

1/T1
(s–1)

4.00
2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

1/T1 (s^-1)

(mM)

6.00

y = 3.7403x + 0.3216
R² = 0.9949

4.00
2.00
0.00
0

0.5

1

1.5

Gd concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.16 T1 data for GdDOTA (7 T, Temp = 19 °C).

6.00

y = 3.7437x + 0.3335
R² = 0.9936

4.00
2.00
0.00
0

0.5

1

Gd concentration (mM)

1.5
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.26
2.96
1.55
0.87
0.55
0.51

0.19
0.34
0.65
1.15
1.83
1.96

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.32
3.15
1.59
0.89
0.57
0.56

0.19
0.32
0.63
1.13
1.77
1.77

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.32
3.15
1.59
0.89
0.57
0.56

0.19
0.32
0.63
1.13
1.77
1.77

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

5.32
3.15
1.59
0.89
0.57
0.56

0.19
0.32
0.63
1.13
1.77
1.77

y = 4.9477x + 0.3517
R² = 0.996

6.00
4.00
2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

1/T1
(s–1)

6.00
4.00

y = 5.0095x + 0.3964
R² = 0.9921

2.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

(mM)

y = 5.0524x + 0.2408
R² = 0.9974

6.00
4.00
2.00
0.00
0

1/T1 (s^-1)
1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.17 T1 data for Cryptate 3.1 (7 T, Temp = 19 °C).

6.00
4.00

2.00

1

1.5

y = 5.0337x + 0.3413
R² = 0.995

2.00
6.00
0.00
4.00

0.5

Eu concentration
y = 3.7403x
+ 0.3216 (mM)
R² = 0.9949

0

0.5

1

1.5

Gd concentration (mM)

0.00
0

0.5

1

Eu concentration (mM)

1.5
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Table 3.18 T1 data for Cryptate 3.2 (7 T, Temp = 19 °C).

1
0.5
0.25
0.125
0.0625
0

7.14
3.73
2.10
1.63
1.04
0.51

0.14
0.27
0.48
0.61
0.96
1.96

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.58
3.97
2.18
1.81
1.16
0.56

0.13
0.25
0.46
0.55
0.86
1.77

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

6.67
3.60
2.01
1.56
1.04
0.50

0.15
0.28
0.50
0.64
0.96
1.99

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.09
3.66
2.11
1.71
1.10
0.54

0.14
0.27
0.48
0.59
0.91
1.86

y = 6.4889x + 0.5986
R² = 0.997

10.00

1/T1 (s^-1)

T1
(s)

5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

1/T1
(s–1)

y = 6.8392x + 0.6675
R² = 0.9953

10.00
5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

y = 3.5511x
0.1733
5.00
10.00
4.00
3.776x +++0.5055
0.1366
y y= =6.1748x
R² = 0.9992
4.00
R²
R² == 0.9979
0.99
3.00
3.00
5.00
2.00
2.00
1.00
0.00
0.00
0.5
1
0.00 0
0
0.5
11
0
0.5
Eu concentration
(mM)
Gd
concentration
Gd concentration (mM)
(mM)

1/T1 (s^-1)
(s^-1)
1/T1
1/T1(s^-1)

(mM)

1/T1 (s^-1)

Concn

10.00

1.5
1.5
1.5

y = 6.3695x + 0.644
R² = 0.9953

5.00
0.00
0

0.5

1

Eu concentration (mM)

1.5
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T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.58
3.46
1.78
1.03
0.65
0.51

0.13
0.29
0.56
0.97
1.54
1.96

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.63
3.51
1.79
1.04
0.67
0.56

0.13
0.29
0.56
0.96
1.49
1.77

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.58
3.51
1.79
1.01
0.64
0.50

0.13
0.29
0.56
0.99
1.55
1.99

Concn
(mM)

1/T1
(s–1)

T1
(s)

1
0.5
0.25
0.125
0.0625
0

7.46
3.50
1.77
1.02
0.67
0.54

0.13
0.29
0.56
0.98
1.50
1.86

10.00

y = 7.1821x + 0.183
R² = 0.9921

5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

1/T1
(s–1)

y = 7.2167x + 0.2029
R² = 0.9913

10.00
5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

(mM)

10.00

y = 7.2076x + 0.1766
R² = 0.993

5.00
0.00
0

0.5

1

1.5

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.19 T1 data for Cryptate 3.3 (7 T, Temp = 19 °C).

10.00

y = 7.069x + 0.2102
R² = 0.993

5.00
0.00
0

0.5

1

Eu concentration (mM)

1.5
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5
2.5
1.25
0

Concn
(mM)
5
2.5
1.25
0

Concn
(mM)
5
2.5
1.25
0

1/T1
(s–1)

T1
(s)

13.08
6.89
3.93
3.01

0.08
0.15
0.25
0.33

1/T1
(s–1)

T1
(s)

13.21
7.10
4.07
3.01

0.08
0.14
0.25
0.33

1/T1
(s–1)

T1
(s)

13.24
7.24
3.62
3.01

0.08
0.14
0.28
0.33

20.00

y = 2.0968x + 2.1401
R² = 0.9691

10.00
0.00
0

2

4

6

Gd concentration (mM)

1/T1 (s^-1)

(mM)

y = 2.1182x + 2.2134
R² = 0.9746

20.00
10.00
0.00
0

2

4

6

Gd concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.20 T1 data for GdDOTA (11.7 T, Temp = 37 °C).

20.00

y = 2.1582x + 2.0559
R² = 0.9636

10.00
0.00
0

2

4

6

Gd concentration (mM)

Concn
(mM)
10
5
2.5
0

Concn
(mM)
7.63
3.825
1.9125
0

1/T1
(s–1)

T1
(s)

29.08
13.28
8.08
3.01

0.03
0.08
0.12
0.33

1/T1
(s–1)

T1
(s)

28.54
14.02
7.97
3.01

0.04
0.07
0.13
0.33

1/T1
(s–1)

T1
(s)

23.53
11.21
6.52
3.01

0.04
0.09
0.15
0.33

y = 2.6244x + 1.8831
R² = 0.9862

40.00
20.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

(mM)
10
5
2.5
0

y = 2.5813x + 2.0913
R² = 0.9931

40.00
20.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.21 T1 data for Cryptate 3.1 (11.7 T, Temp = 37 °C).

40.00

y = 2.7305x + 1.9453
R² = 0.9855

20.00
0.00
0

5
Eu concentration (mM)

10
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Concn
(mM)
10
5
2.5
0

Concn
(mM)
7.63
3.825
1.9125
0

T1
(s)

36.19
17.03
9.23
3.01

0.03
0.06
0.11
0.33

1/T1
(s–1)

T1
(s)

35.54
18.34
9.29
3.01

0.03
0.05
0.11
0.33

1/T1
(s–1)

T1
(s)

27.93
13.88
7.05
3.01

0.04
0.07
0.14
0.33

y = 3.3596x + 1.6698
R² = 0.9913

40.00
20.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

(mM)
10
5
2.5
0

1/T1
(s–1)

40.00
20.00

y = 3.3054x + 2.0834
R² = 0.9963

0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.22 T1 data for Cryptate 3.2 (11.7 T, Temp = 37 °C).

40.00

y = 3.3404x + 1.8072
R² = 0.9898

20.00
0.00
0

5

10

Eu concentration (mM)

(mM)
13
6.5
3.25
0

Concn
(mM)
13
6.5
3.25
0

1/T1
(s–1)

T1
(s)

63.86
28.23
14.52
3.01

0.02
0.04
0.07
0.33

1/T1
(s–1)

T1
(s)

65.36
29.06
14.45
3.01

0.02
0.03
0.07
0.33

100.00

y = 4.7321x + 0.4932
R² = 0.9901

50.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.23 T1 data for Cryptate 3.3 (11.7 T, Temp = 37 °C).

100.00
50.00
0.00

y = 4.8603x + 0.3274
R² = 0.9902
0

5

10

Eu concentration (mM)

15
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5
2.5
1.25
0

Concn
(mM)
5
2.5
1.25
0

Concn
(mM)
5
2.5
1.25
0

T1
(s)

16.89
8.79
4.73
2.84

0.06
0.11
0.21
0.35

1/T1
(s–1)

T1
(s)

16.83
8.77
4.72
3.01

0.06
0.11
0.21
0.35

1/T1
(s–1)

T1
(s)

16.88
8.77
4.71
3.01

0.06
0.11
0.21
0.35

y = 2.8959x + 1.9774
R² = 0.9839

20.00
10.00
0.00
0

2

4

6

Gd concentration (mM)

1/T1 (s^-1)

(mM)

1/T1
(s–1)

y = 2.8814x + 1.9902
R² = 0.9837

20.00
10.00
0.00
0

2

4

6

Gd concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.24 T1 data for GdDOTA (11.7 T, Temp = 20 °C).

y = 2.8928x + 1.9776
R² = 0.9834

20.00
10.00
0.00
0

2

4

6

Gd concentration (mM)

Concn
(mM)
10
5
2.5
0

Concn
(mM)
7.63
3.825
1.9125
0

T1
(s)

41.19
22.20
10.90
2.84

0.02
0.05
0.09
0.35

1/T1
(s–1)

T1
(s)

40.78
18.47
10.41
3.01

0.02
0.05
0.10
0.35

1/T1
(s–1)

T1
(s)

34.89
16.88
8.87
3.01

0.03
0.06
0.11
0.35

y = 3.8888x + 2.268
R² = 0.9979

50.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

(mM)
10
5
2.5
0

1/T1
(s–1)

y = 3.8204x + 1.4158
R² = 0.9902

50.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.25 T1 data for Cryptate 3.1 (11.7 T, Temp = 20 °C).

40.00

y = 4.258x + 1.6452
R² = 0.9931

20.00
0.00
0

5
Eu concentration (mM)

10
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(mM)
10
5
2.5
0

Concn
(mM)
10
5
2.5
0

1/T1
(s–1)

T1
(s)

49.70
24.30
12.57
2.84

0.02
0.04
0.08
0.35

1/T1
(s–1)

T1
(s)

50.10
26.12
12.70
3.01

0.02
0.04
0.08
0.35

y = 4.7305x + 1.6612
R² = 0.9969

60.00
40.00
20.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.26 T1 data for Cryptate 3.2 (11.7 T, Temp = 20 °C).

y = 4.7878x + 1.9956
R² = 0.9981

60.00
40.00
20.00
0.00
0

5

10

15

Concn
(mM)
7.63
3.825
1.9125
0

1/T1
(s–1)

T1
(s)

39.98
19.83
10.40
3.01

0.03
0.05
0.10
0.35

1/T1 (s^-1)

Eu concentration (mM)
y = 4.9201x + 1.8244
R² = 0.9964

60.00
40.00
20.00
0.00
0

5

10

Eu concentration (mM)

(mM)
13
6.5
3.25
0

Concn
(mM)
13
6.5
3.25
0

1/T1
(s–1)

T1
(s)

84.75
39.64
19.77
2.84

0.01
0.03
0.05
0.35

1/T1
(s–1)

T1
(s)

84.82
38.62
20.01
3.01

0.01
0.03
0.05
0.35

y = 6.3573x + 0.5911
R² = 0.9961

100.00
50.00
0.00
0

5

10

15

Eu concentration (mM)

1/T1 (s^-1)

Concn

1/T1 (s^-1)

Table 3.27 T1 data for Cryptate 3.3 (11.7 T, Temp = 20 °C).

100.00

y = 6.3469x + 0.4789
R² = 0.9947

50.00
0.00
0

5

10

Eu concentration (mM)

15

95
3.5.4 Synthesis
Scheme 3.2 Synthetic route to cryptate 3.3.

3-(Biphenyl-4-yl)propane-1,2-diol (3.4): To a mixture of 4-allylbiphenyl (4.00 g, 20.6
mmol, 1 equiv), t-BuOH (150 mL), and H2O (150 mL) was added sequentially K3Fe(CN)6
(20.3 g, 61.8 mmol, 3 equiv), K2CO3∙H2O (9.65 g, 61.8 mmol, 3 equiv), and a solution of
OsO4 in t-BuOH (95.9 mM, 2.70 mL, 0.0129 equiv). The reaction mixture was stirred for
20 h at ambient temperature at which point Na2SO3 (7.79 g, 61.8 mmol, 3 equiv) was
added, and stirring was continued for 4 h. The resulting solution was concentrated to
dryness under reduced pressure, and the residue was extracted with Et2O (6 × 50 mL).
After removal of Et2O under reduced pressure, purification was performed using silica gel
chromatography (1:1 hexanes/ethyl acetate) to yield 4.25 g (90%) of 3.4 as white solid. 1H
NMR (400 MHz, CD3OD, ): 2.66–2.90 (m, CH2, 2H), 3.44–3.56 (m, CH2, 2H), 3.81–3.89
(m, CH, 1H), 7.24–7.58 (m, CH, 9H); 13C NMR (101 MHz, CD3OD, ): 40.5 (CH2), 66.6
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(CH2), 74.4 (CH), 127.80 (CH), 127.81 (CH), 128.1 (CH), 129.8 (CH), 130.9 (CH), 139.3,
140.3, 142.2; TLC: Rf = 0.33 (1:1 hexanes/ethyl acetate); HRESIMS (m/z): [M + Na]+
calcd for C15H16O2Na, 251.1048; found, 251.1046.
4-(1,2-Bis(allyloxy)ethyl)biphenyl (3.5): To a solution of 3.4 (3.10 g, 13.5 mmol, 1 equiv)
in anhydrous dimethoxyethane (60 mL) under Ar at ambient temperature was added NaH
(2.53 g, 52.6 mmol, 4 equiv) followed by the dropwise addition of 1-bromoprop-2-ene
(4.45 mL, 52.6 mmol, 4 equiv). The resulting reaction mixture was heated at reflux for 23
h and allowed to cool to ambient temperature before excess NaH was quenched with
methanol (2 mL). Solvent was removed under reduced pressure; the resulting residue was
extracted with ethyl acetate (3 × 20 mL); and the combined ethyl acetate solutions were
washed with water (3 × 20 mL). The organic phase was dried over Na2SO4 and
concentrated under reduced pressure. Purification was performed using silica gel
chromatography (9:1 hexanes/ethyl acetate) to yield 3.85 g (95%) of 3.5 as a yellow oil. 1H
NMR (400 MHz, CD3CN, ): 2.79–2.91 (m, CH2, 2H), 3.37–3.48 (m, CH2, 2H), 3.68–3.76
(m, CH, 1H), 3.93–4.11 (m, CH2, 4H), 5.04–5.32 (m, CH2, 4H), 5.78–5.98 (m, CH, 2H),
7.28–7.66 (m, CH, 9H);

13

C NMR (101 MHz, CD3CN, ): 38.1 (CH2), 72.3 (CH2), 72.6

(CH2), 79.8 (CH), 116.4 (CH2), 116.7 (CH2), 127.6 (CH), 127.7 (CH), 128.1 (CH), 129.8
(CH), 131.0 (CH), 136.2 (CH), 136.6 (CH), 139.2, 139.5, 141.6; TLC: Rf = 0.53 (9:1
hexanes/ethyl acetate); HRESIMS (m/z): [M + Na]+ calcd for C21H24O2Na, 331.1674;
found, 331.1669.
2,2’-(Propane-1,2-diylbisoxy-3-biphenyl-4-yl)-diethanol (3.6):

Ozone was passed

through a solution of 5 (4.00 g, 12.9 mmol, 1 equiv) in methanol (100 mL) at –50 °C until
the starting compound was consumed (55 min). The resulting reaction mixture was purged
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with Ar, and NaBH4 (4.87 g, 129 mmol, 10 equiv) was added. The mixture was stirred for
1 h, a mixture of HOAc/H2O 1:10 (v/v) (18 mL) was added, and the resulting solution was
stirred for 2 h. Volatile components were removed under reduced pressure, and the residue
was extracted with ethyl acetate (6 × 20 mL). The extract was concentrated under reduced
pressure, and purification was performed using silica gel chromatography (ethyl acetate) to
yield 3.31 g (81%) of 3.6 as pale yellow oil. 1H NMR (400 MHz, CD3CN, ): 2.75–2.90
(m, CH2, 2H), 3.01 (brs, OH, 2H), 3.25–3.77 (m, CH and CH2, 11H), 7.29–7.68 (m, CH,
9H);

13

C NMR (101 MHz, CD3CN, ): 38.1 (CH2), 61.9 (CH2), 62.2 (CH2), 72.3 (CH2),

73.3 (CH2), 73.6 (CH2), 80.8 (CH), 127.6 (CH), 127.7 (CH), 128.2 (CH), 129.8 (CH),
131.0 (CH), 139.1, 139.6, 141.6; TLC: Rf = 0.44 (ethyl acetate); HRESIMS (m/z): [M +
H]+ calcd for C19H25O4, 317.1753; found, 317.1745.
2,2’-(Propane-1,2-diylbisoxy-3-biphenyl-4-yl)-ditosylate (3.7):

A solution of tosyl

chloride (3.71 g, 19.5 mmol, 3 equiv) in CH2Cl2 (22 mL) was added in a dropwise manner
to an ice-cooled solution of 3.6 (2.06 g, 6.51 mmol, 1 equiv), triethylamine (5.45 mL, 39.1
mmol, 6 equiv), and dimethylaminopyridine (0.030 mL, 0.25 mmol, 0.038 equiv) in
CH2Cl2 (33 mL), and the resulting mixture was stirred for 24 h while warming to ambient
temperature. The reaction mixture was washed sequentially with water (2 × 33 mL),
saturated aqueous Na2CO3 (2 × 22 mL), and saturated aqueous citric acid (2 × 22 mL);
dried over Na2SO4; and concentrated under reduced pressure. Purification was performed
using silica gel chromatography (stepwise gradient of 3:1→1:1 hexanes/ethyl acetate) to
yield 3.15 g (78%) of 3.7 as a light yellow oil. 1H NMR (400 MHz, CD3CN, ): 2.37 (s,
CH3, 6H), 2.60–2.74 (m, CH2, 2H), 3.20–3.35 (m, CH2, 2H), 3.47–3.58–3.67 (m, CH and
CH2, 5H), 3.97–4.12 (m, CH2, 4H), 7.18–7.81 (m, CH, 17H);
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C NMR (101 MHz,
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CD3CN, ): 21.6 (CH3), 37.7 (CH2), 68.2 (CH2), 69.3 (CH2), 70.8 (CH2), 71.1 (CH2), 73.1
(CH2), 80.7 (CH), 127.6 (CH), 127.7 (CH), 128.2 (CH), 128.7 (CH), 129.8 (CH), 131.0
(CH), 133.8, 138.6, 139.5, 141.6, 146.3; TLC: Rf = 0.21 (3:1 hexanes/ethyl acetate);
HRESIMS (m/z): [M + Na]+ calcd for C33H36O8S2Na, 647.1749; found, 647.1735.
5-(Biphenyl-4-ylmethyl)-4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane
(3.8): Under an atmosphere of Ar, 4,13-diaza-18-crown-6-ether (0.177 g, 0.675 mmol, 1
equiv) was added to a suspension of Cs2CO3 (1.08 g, 3.33 mmol, 4.93 equiv) in anhydrous
acetonitrile (37 mL). The mixture was heated to 60 °C, and a solution of 7 (0.478 g, 0.765,
1.13 equiv) in anhydrous acetonitrile (13 mL) was added. The reaction mixture was heated
at reflux for 115 h, cooled to ambient temperature, and filtered through celite. Solvent was
removed under reduced pressure, and purification was performed using silica gel
chromatography (stepwise gradient of 20:1→10:1 CH2Cl2/methanol) to yield 73.6 mg
(21%) of 3.8 as a pale yellow oil. 1H NMR (400 MHz, CD3CN, ): 2.55–2.88 (m, 10H),
3.03–3.11 (m, 1H), 3.32–3.82 (m, 26H), 7.30–7.66 (m, CH, 9H);
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C NMR (101 MHz,

CD3CN, ): 38.4 (CH2), 53.4 (CH2), 53.5 (CH2), 53.7 (CH2), 53.8 (CH2), 54.1 (CH2), 54.3
(CH2), 66.1 (CH2), 68.0 (CH2), 68.1 (CH2), 68.57 (CH2), 68.59 (CH2), 68.8 (CH2), 68.9
(CH2), 69.2 (CH2), 69.6 (CH2), 71.4 (CH2), 79.4 (CH), 126.7 (CH), 127.7 (CH), 127.8
(CH), 128.3 (CH), 129.2 (CH), 129.9 (CH), 131.0 (CH), 138.4, 139.6, 141.5; TLC: Rf =
0.23 (10:1 CH2Cl2/methanol); HRESIMS (m/z): [M + H]+ calcd for C31H47O6N2, 543.3434;
found, 543.3425.
General Procedure for the synthesis of EuII-containing cryptates (3.1–3.3): A degassed
aqueous solution of EuCl2 (1 equiv) was mixed with a degassed aqueous solution of a
cryptand (2 equiv). The resulting mixture was stirred for 12 h at ambient temperature under
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Ar. Degassed PBS (10×) was added to make the entire reaction mixture 1× in PBS, and
stirring was continued for 30 min. The concentration of Eu was verified by ICP-MS.
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3.7 Estimating Rotational Correlation Time (τR)
3.7.1 Theoretical Basis
Inner-sphere relaxivity can be expressed by the following equation:
Eq 3.2

(

-

)

where q is the number of inner-sphere water molecules, T1m is the longitudinal relaxation
time of a bound water molecule, τm is the residence lifetime of bound water molecules.
Assuming that the inner-sphere relaxivity of a sample is contributing to half the observed
relaxivity, r1,obs, Eq 3.2 can be rewritten as:
(

Eq 3.3

)

where 1000 was used as a factor to convert mM unit in relaxivity to M.
Solving for T1m:
Eq 3.4

(

)

There are two relaxation mechanisms of the bound water protons that depend on the
interaction between the paramagnetic metal and the water proton—dipole–dipole (through
space) and scalar (through bonds) and are expressed by the equation below:
Eq 3.5
The longitudinal relaxation rate of water proton due to dipole-dipole mechanism is
described by the following equation:
Eq 3.6
where

(

)

( ) (

)

is the proton gyromagnetic ratio (2.67 × 108 rad s–1 T–1),

(9.27 × 10–24 J T–1),

is Bohr magneton

is the distance between Eu2+ and water proton (3.22 × 10–10 m), S

is the spin number (3.5 for Eu2+),

is the magnetic permeability constant (4π × 10–7 T•m
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A–1),

and

are the longitudinal and transverse correlation times, respectively,

the nuclear Larmor frequency (
electronic Larmor frequency (

multiplied with magnetic field strength , and

is
is the

multiplied with magnetic field strength).

The longitudinal and transverse correlation rates,

and

respectively

are

mathematically described as:
Eq 3.7
Eq 3.8
where

is the rotational correlation time, and

are longitudinal and transverse

electronic relaxation times, respectively.
3.7.2 Calculating

using Microsoft Excel Spreadsheet

1. Input the values of q (cell F1), r1(obs) (cell F2), taum (cell F3), g-factor (cell H1),
r(EuH) (cell H2), and S (cell H3). Values for T1m (cell B1) and (1/T1m)/c (cell B4) will
be automatically calculated.

Note: Shown below are the MS excel functions for T1m (cell B1) and (1/T1m)/c (cell
B4):
Eq 3.9 T1m (cell B1): =(F1/(0.7*55.5*F2*1000))-F3
where Eq 3.9 was based from Eq 3.4. (1/T1m)/c (cell B4) has the following formula:
Eq 3.10 (1/T1m)/c (cell B4): =(1/B1)/((2/15)*(((267000000^2)*(H1^2)*((9.27E24)^2))/((H2)^6))*((0.0000001)^2)*(H3*(H3+1)))
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Eq 3.10 is derived from Eq 3.6 and has the following equation:
Eq 3.11
(

)

(

)

The derived equation shown in Eq 3.11 is equivalent to Eq 3.12
Eq 3.12 (

)

which is the basis for the function in cell B8:
Eq 3.13 (1/T1m)/c (cell B4): =(3*B12/(1+((F8)^2)*B12^2))+(7*B13)/(1+((F9)^2)
*B13^2)
2. Input the magnetic field strength, B, (cell H8) to compute for the nuclear and electronic
Larmor frequency, proton LF (cell F8) and electron LF (cell F9), respectively.

Note: Shown below are the MS excel functions for tc1 (cell B12) and tc2 (cell B12):
Eq 3.14 tc1 (cell B12): =B17/(1+((1/F3)+(F12))*B17)
Eq 3.15 tc2 (cell B13): =B17/(1+((1/F3)+(F13))*B17)
Eq 3.14 and 3.15 are based from Eq 3.7 and 3.8.
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3. Input the 1/T1e and 1/T2e values.

4. Input tauR values until (1/T1m)/c value in cell B8 is equal to that in cell B4.
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3.8 1H and 13C NMR Spectra of 3.4–3.8

Figure 3.14 1H NMR Spectrum of 3.4.
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Figure 3.15 13C NMR Spectrum of 3.4.
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Figure 3.16 1H NMR Spectrum of 3.5.
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Figure 3.17 13C NMR Spectrum of 3.5.
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Figure 3.18 1H NMR Spectrum of 3.6.
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Figure 3.19 13C NMR Spectrum of 3.6.
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Figure 3.20 1H NMR Spectrum of 3.7.
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Figure 3.21 13C NMR Spectrum of 3.7.
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Figure 3.22 1H NMR Spectrum of 3.8.
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Figure 3.23 13C NMR Spectrum of 3.8.
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Chapter Four
Stability of Eu2+-Containing Cryptates
Portions of this chapter were reprinted or adapted with permission from:
Garcia, J.; Kuda-Wedagedara, A. N. W.; Allen, M. J. Physical Properties of Eu2+Containing Cryptates as Contrast Agents for Ultrahigh-Field Magnetic Resonance Imaging
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4.1 Introduction
Kinetic stability, which relates to the inertness of a complex to transmetallation in vivo,
is a critical parameter for contrast agents. Weaver and coworkers have reported the
stability of cryptate Eu-4.1 in the presence of Na+, Ba2+, and tetraethylammonium cations,
which are components of electrolytes in cyclic voltammetric experiments.1 However, the
kinetic stability of Eu2+-containing cryptates in the presence of biologically relevant ions,
which include Ca2+, Mg2+, and Zn2+, is of the utmost importance due to the toxicity of
uncomplexed europium.2 Therefore, our kinetic studies explored the stability of the Eu2+containing complexes of cryptands 4.1–4.4, which contain a variety of functional groups
(Figure 4.1), in the presence of Ca2+, Mg2+, and Zn2+. The use of these ligands allowed us
to establish the relationship between the ligand structure and kinetic stability. Additionally,
understanding the structural characteristics of Eu2+-containing cryptates that influence
relaxivity as a function of pH value, temperature, and magnetic field strength is important
because this knowledge should enable the design of improved ligands for use at ultrahigh
field strengths.
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Figure 4.1 Structures of cryptands 4.1–4.4.
4.2 Synthesis
The synthesis of cryptands 4.3 and 4.4 was performed by Akhila Kuda-Wedagedara, a
graduate student of the Allen laboratory. To synthesize cryptands 4.3 and 4.4, a two-step
synthetic procedure was used that involved thionyl chloride and 1,4,10,13-tetraoxa-7,16diazacyclooctadecane (diazacrown ether). Briefly, the diacids were converted into diacid
chlorides followed by immediate reaction with diazacrown ether to produce the desired
cryptands (Scheme 4.1).
Scheme 4.1 Synthesis of 4.3 and 4.4.
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4.3 Kinetic Stability Studies
One critical feature of a useful contrast agent is its stability towards dechelation under
physiological conditions. Although the thermodynamic stability constant of Eu–4.1 is high
(log K = 13.0),3 kinetic stability is also crucial to evaluate the possibility of demetallation
of contrast agents in the presence of endogenous ions. For a small-molecule contrast agent
to be used in vivo, it should be kinetically inert for at least long enough to be excreted
(t1/2 ≈ 5–6 min in mice, t1/2 ≈ 90 min in humans).4 Kinetic stability is important because
uncomplexed Eu2+ oxidizes to Eu3+ more easily than Eu2+ that is encapsulated in
cryptands,5 and Eu3+ is toxic.2 Prior to excretion, one possible pathway for the release of
Eu2+ is through transmetallation with endogenous ions. Ions that are found in blood plasma
include Ca2+, Mg2+, and Zn2+ and these are of particular concern because of their
abundance in serum and their tendency to be complexed by ligands. Uncomplexed
Ca2+ and Mg2+ ions, despite having a lower affinity than Zn2+ for many ligands,6 are
present in higher concentrations than Zn2+ in blood serum (1.05, 1.34, and 0.125 mM for
Ca2+, Mg2+, and Zn2+, respectively).6–8 However, the relatively low concentration of zinc in
serum is sufficient to displace gadolinium in diethylenetriamine pentaacetate.6,9 Therefore,
we have examined the stability of Eu2+-containing cryptates Eu–4.1–Eu–4.4 towards
transmetallation by monitoring the change in the longitudinal relaxation rate of water
protons at 60 MHz in the presence of Ca2+, Mg2+, and Zn2+ following the procedure of
Muller and coworkers.6,9 An Eu2+-containing complex was prepared in degassed phosphate
buffered saline (PBS) and other metals were added to the solution. The Eu 2+ complexes are
soluble in PBS, however, uncomplexed Eu2+ is insoluble, and upon transmetallation, it
immediately precipitates.10 Once Eu2+precipitates, a measurable decrease in the relaxation
rate of the water protons is detected. A plot of the ratio of the longitudinal relaxation rates
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(R1p) of the Eu2+-containing solutions at a time (t) relative to initial values (t = 0)
vs. t allows the extent of transmetallation to be monitored. Muller and coworkers
developed this technique as a way to measure the degree of transmetallation in terms of the
kinetic index, which is defined as the time required to reach 80% (at this point 80% of the
Eu2+ is dechelated by transmetallion with the endogenous ions) of the initial longitudinal
relaxation rate of water protons. We used concentrations of Ca2+, Mg2+, and Zn2+ that are
2.38, 1.87, and 20 times greater than normal in vivo levels, respectively, and the results of

R1p(t)/R1p(t = 0)

our experiments are shown in Figures 4.2, 4.3, 4.4, and Table 4.1.
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Figure 4.2 Evolution of R1p(t)/R1p(t=0) versus time for the Eu2+-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM) in the presence of Ca2+ (2.5
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent
standard error of the mean.
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Figure 4.3 Evolution of R1p(t)/R1p(t=0) versus time for the Eu2+-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM) in the presence of Mg2+ (2.5
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent

R1p(t)/R1p(t = 0)

standard error of the mean.
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Figure 4.4 Evolution of R1p(t)/R1p(t=0) versus time for the Eu2+-containing cryptates Eu–
4.1 (♦), Eu–4.2 (■), Eu–4.3 (▲), and Eu–4.4 (●) (2.5 mM) in the presence of Zn2+ (2.5
mM). The horizontal line at 0.8 is the threshold for the kinetic index. Error bars represent
standard error of the mean.
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Table 4.1 Calculated %Eu2+ dechelated via transmetalation in the presence of Ca2+, Mg2+,
and Zn2+ after 4740 min (Ca2+), 4770 min (Mg2+), and 4800 min (Zn2+) treatment of 2.5
mM of the corresponding endogeneous ions.
Complexes

Ca2+ (%)

Mg2+ (%)

Zn2+ (%)

Eu–4.1

9

4

7

Eu–4.2

17

8

14

As seen from the ratio of the longitudinal relaxation rates vs. t (Figures 4.2, 4.3,
and 4.4), the kinetic indices of Eu–4.1 and Eu–4.2 are greater than 4740 min in the
presence of Ca2+, Mg2+, and Zn2+(Table 4.2), which is more than 53 times longer than the
half-life of small molecules in vivo. This kinetic index indicates that Eu–4.1 and Eu–
4.2 did not fall below 80% of their efficacy during this time, which suggests that these
complexes are inert to transmetallation in the presence of Ca2+, Mg2+, and Zn2+ at greater
than normal in vivo levels. Interestingly, the values in the presence of Zn2+ appeared to
decrease initially and then increase again; however, analysis of the variance revealed that
all of the data points for Eu–4.1 and Eu–4.2 in the presence of Zn2+ are not different (α =
0.01). The stability of these Eu2+-containing complexes is likely due to the effective
binding of the cryptand to the metal ion.
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Table 4.2 Kinetic index data.
Ca2+ (min)

Mg2+ (min)

Zn2+ (min)

Eu–4.1

>4740

>4770

>4800

Eu–4.2

>4740

>4770

>4800

Eu–4.3

>0,<90

>0,<120

>0,<240

Eu–4.4

>0,<90

>0,<120

>150,<240

Complexes

Although Eu–4.1 and Eu–4.2 showed stability towards transmetallation in the presence
of endogenous metal ions, precipitates were observed as soon as PBS was added to Eu–
4.3 and Eu–4.4, consequently, these data are not included in Figures 4.1, 4.2, and 4.3. This
observation

suggests

a

weaker

interaction

between

Eu2+ and

amide-

containing 4.3 and 4.4 relative to 4.1 and 4.2. A further decrease in the longitudinal
relaxation rate was observed in the presence of Ca2+, Mg2+, and Zn2+. Studies with Eu–
3 and Eu–4 were stopped once the longitudinal relaxation rate fell below 80 % of the initial
value.
The weak binding of Eu2+ to 4.3 and 4.4 can be attributed to the presence of amide
groups in the cryptand structure. Amides have resonance structures (Figure 4.5) that
change both the electronic and structural properties of the ligands relative to 4.1 and 4.2.
Because of the presence of partial positive charges on nitrogen atoms, it is unlikely that
these nitrogen atoms serve as donors. Thus, the denticity of 4.3 and 4.4 is decreased
relative to that of 4.1 and 4.2. Furthermore, when the lone pairs on the nitrogen atoms are
delocalized, the geometry of the nitrogen atoms changes from pyramidal to trigonal planar,
and this change in geometry could also make it harder for Eu2+ to coordinate with 4.3 and
4.4 relative to 4.1 and 4.2. Consequently, a decrease in the kinetic stability is observed.
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Although amide-containing cryptands are not good ligands for Eu2+, Eu–4.1 and Eu–
4.2 were observed to have high kinetic stabilities in the presence of Ca2+, Mg2+, and Zn2+ in
concentrations higher than those found in vivo, a promising result for their potential use as
contrast agents.

Figure 4.5 Contributing resonance structures of cryptands 4.3 and 4.4.
4.4 Conclusion
Eu2+-containing cryptates that have no amide moieties in their structures were
kinetically stable in the presence of Ca2+, Mg2+, and Zn2+at concentrations 1.87–20 times
higher than biological concentrations. In addition, transmetallation studies demonstrated
that the kinetic stability of Eu2+-containing cryptates is affected by the presence of amides.
4.5 Experimental Section
4.5.1 Materials
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB
Ultra Mk2 water purification system (ELGA). Dicholoromethane was dried using a solvent
purification system (Vacuum Atmospheres Company) and degassed under vacuum.
Triethylamine
chromatography

was
was

distilled

from

performed

CaH2 under

using

silica

an
gel

atmosphere
60,

230–400

of

Ar.11 Flash

mesh

(EMD

Chemicals).12 Analytical TLC was carried out with ASTM TLC plates precoated with
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silica gel 60 F254 (250 μm layer thickness). TLC visualization was accomplished using a
UV lamp followed by charring with potassium permanganate stain (2 g of KMnO4, 20 g of
K2CO3, 5 mL of 5% w/v aqueous NaOH, 300 mL of H2O).
4.5.2 Characterization
1

H NMR spectra were obtained with a Varian Unity 400 (400 MHz) spectrometer,

and 13C NMR spectra were obtained with a Varian Unity 400 (101 MHz) spectrometer.
Chemical shifts are reported relative to residual solvent signals (CDCl3: 1H: δ = 7.27,
13

C: δ = 77.23 ppm). 1H NMR spectroscopic data are assumed to be first order, and the

apparent multiplicity is reported as d = doublet and m = multiplet. HRMS (ESI) were
obtained with an electrospray time-of-flight high-resolution Waters Micromass LCT
Premier XE mass spectrometer. Samples for inductively coupled plasma mass
spectrometry (ICP-MS) were diluted using aqueous nitric acid (2 % v/v). Standard
solutions were prepared by serial dilution of a Eu standard (High-Purity Standards). ICPMS measurements were conducted with a PE Sciex Elan 9000 ICP-MS instrument with a
cross-flow nebulizer and Scott-type spray chamber. Longitudinal relaxation times, T1, were
measured using standard recovery methods with a Bruker Minispec mq 60 [1.4 T] at 60
MHz and 37 °C.
4.5.3 Synthesis
4,7,21,24-tetraoxa-13,16-dithia-1,10-diazabicyclo[8.8.8]hexacosane-11,18-dione (4.3).
A solution of (ethylenedithio)diacetic acid (0.500 g, 2.38 mmol) in thionyl chloride (5.0
mL, 68 mmol) under Ar was heated at reflux for 5 h. Excess thionyl chloride was removed
under reduced pressure, and the residue was dissolved in anhydrous toluene (40 mL). The
resulting solution and a solution of 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane and
triethylamine (1.5 mL, 0.010 mol, 4.2 equiv) in anhydrous toluene (40 mL) were added
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simultaneously (50 mL/h) to a separate flask containing anhydrous toluene (100 mL) at 0–
5 oC under an Ar atmosphere. The resulting solution was stirred for 12 h at ambient
temperature. A yellow–orange suspension formed and was filtered, and the solvent from
the filtrate was removed under reduced pressure. Purification using silica gel
chromatography (10:1 CH2Cl2/methanol) yielded 0.215 g (43%) of 4.3 a fluffy yellow
solid. 1H NMR (400 MHz, CDCl3, δ): 2.77–4.32 (m, CH2); 13C NMR (101 MHz, CDCl3,
δ): 32.9 (CH2), 33.6 (CH2), 49.7 (CH2), 50.5 (CH2), 69.2 (CH2), 69.5 (CH2), 71.2 (CH2),
71.4 (CH2), 170.7; TLC: Rf = 0.54 (10:1 CH2Cl2/methanol); HRESIMS (m/z): [M + Na]+
calcd for NaC18H32N2S2O6, 459.1600; found, 459.1602.
5,6-benzo-4,7,13,16,20,23-hexaoxa-1,10-diazabicyclo[8.8.8]hex-acosane-2,9-dione
(4.4). A solution of catechole-1,4-o,o-diacetic acid (0.40 g, 1.8 mmol) in thionyl chloride
(5.0 mL, 68 mmol) under Ar was heated at reflux for 5 h. Excess thionyl chloride was
removed under reduced pressure, and the residue was dissolved in anhydrous toluene (25
mL).

The

resulting

solution

and

a

solution

of

1,4,10,13-tetraoxa-7,16-

diazacyclooctadecane (0.32 g, 1.2 mmol, 1.0 equiv) and triethylamine (0.50 mL, 3.3
mmol, 2.4 equiv) in anhydrous toluene (25 mL) were added simultaneously (50 mL/h) to a
separate flask containing anhydrous toluene (60 mL) at 0–5 oC under an Ar atmosphere.
The solution was stirred for 12 h at ambient temperature. An orange suspension formed
and was filtered, and the solvent was removed under reduced pressure. Purification using
silica gel chromatography (9:1 CH2Cl2/methanol) yielded 0.144 g (36%) of 4.4 a fluffy
white solid. 1H NMR (400 MHz, CDCl3, δ): 2.77–3.22 (m, CH2, 2H), 3.37–3.83 (m, CH2,
20H), 4.08–4.35 (m, CH2, 2H), 4.64–4.91 (m, CH2, 2H), 5.15–5.23 (d, J = 14.4 Hz, CH2,
2H), 6.86–7.10 (m, CH, 4H);

13

C NMR (101 MHz, CDCl3, δ): 48.5 (CH2), 48.9 (CH2),

68.1 (CH2), 69.4 (CH2), 69.7 (CH2), 71.1 (CH2), 71.3 (CH2), 116.1 (CH), 122.2 (CH),
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148.3, 169.0; TLC: Rf = 0.8 (9:1 CH2Cl2/methanol); HRESIMS (m/z): [M + Na]+ calcd for
NaC22H32N2O8, 475.2062; found, 475.2060.
General Procedure for the Synthesis of Eu–4.1–Eu–4.4: A degassed aqueous solution of
EuCl2 (1 equiv.) was mixed with a degassed aqueous solution of a cryptand (2 equiv.). The
resulting mixture was stirred for 12 h at ambient temperature under Ar. Degassed PBS
(10×) was added, and stirring was continued for 30 min. The concentration of Eu in the
resulting solution was verified by ICP-MS, and the solution was used directly for relaxivity
measurements. For transmetallation experiments, the same procedure was followed with
only 1 equiv. of ligand.
4.5.4 Transmetallation Kinetics
The following procedure was adapted from Muller and coworkers.9 A stock solution of
the Eu2+-containing cryptate (5 mM) was prepared in degassed PBS under an Ar
atmosphere. To an aliquot of this solution was added a solution of Ca2+ (12.1 mM) in
degassed PBS such that the resulting solution was 2.5 mM in both Eu2+ and Ca2+. This
solution was stirred at 37 °C under Ar. Aliquots were taken at 90, 180, 420, 1500, 3300,
and 4740 min after the addition of Ca2+. All aliquots were filtered using 0.2 μm filters prior
to T1 measurements. The t1 value of these aliquots (60 MHz, 37 °C) was immediately
measured at each time point. The experiment was triplicated with independently prepared
solutions. The entire procedure was repeated using Mg2+ (16.4 mM) and Zn2+ (9.97 mM) in
place of Ca2+ (12.1 mM). Statistical analysis of variance was performed using the program
found at faculty.vassar.edu/lowry/anova1u.html.
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4.7 1H and 13C NMR Spectra of 4.3 and 4.4

Figure 4.6 1H NMR Spectrum of 4.3.
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Figure 4.7 13C NMR Spectrum of 4.3.
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Figure 4.8 1H NMR Spectrum of 4.4.
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Figure 4.9 13C NMR Spectrum of 4.4.
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Chapter Five
Interaction of Biphenyl Functionalized Eu2+-Containing Cryptate with Albumin
Binding: Implications to Contrast Agents in MRI
Reprinted from Inorg. Chim. Acta, 393, Garcia, J.; Allen, M. J., Interaction of biphenylfunctionalized Eu2+-containing cryptate with albumin: Implications to contrast agents in
magnetic resonance imaging, 324–327, 2012. Copyright (2012), with permission from
Elsevier.
5.1 Introduction
Magnetic resonance imaging (MRI) is a noninvasive imaging modality that can be used
to study anatomical structures,1 and the use of ultra-high field strength (≥7 T) magnets
enables faster acquisition of MR images with increased spatial resolution.2–4 However,
common contrast agents such as low-molecular-weight Gd3+-containing complexes
become less efficient at ultra-high field strengths relative to lower field strengths.5 Unlike
these Gd3+-based contrast agents, Eu2+-containing cryptates have higher relaxivity values
at ultra-high field strengths (7 and 9.4 T) than at lower field strengths (1.4 and 3 T).6–7
I hypothesized that the relaxivity of Eu2+-containing cryptates could be increased by
using strategies that improve the relaxivity of Gd3+-based agents. One of these strategies is
the slowing of molecular-tumbling rate that can be influenced by covalent or noncovalent
interactions with macromolecules including proteins.1,8–27 Human serum albumin (HSA),
the most abundant protein in plasma with concentration of ∼670 μM or 4.5% (w/v),16
noncovalently binds to some contrast agents that contain lipophilic moieties.16–25 McMurry
and coworkers reported an increase in relaxivity of over 200% as a result of the
noncovalent interaction of albumin with a Gd3+-containing complex functionalized with
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biphenyl.25 Because of the work with Gd3+ and the ability to influence the properties of
Eu2+ with functionalized cryptands,28 we hypothesized that a cryptand with a biphenyl
group would produce a Eu2+complex that interacts with albumin to result in an increase in
relaxivity.
To

test

my

hypothesis,

I

synthesized

biphenyl-modified

Eu2+-containing

cryptate 5.1 (Figure 5.1), and measured the relaxivity of cryptate 5.1 in the presence and
absence of HSA at different field strengths (1.4, 3, 7, 9.4, and 11.7 T). I compared the
resulting relaxivity values to estimates calculated using the Solomon–Bloembergen–
Morgan equations.29 I also illustrated the effect of albumin on the contrast-enhancing
ability of 5.1 using phantom images acquired at 7 T. Finally, I performed variabletemperature 17O NMR experiments that probed the molecular basis of the relaxivity values
of complex 5.1 in the presence and absence of HSA.

Figure 5.1 Structure of biphenyl-functionalized Eu2+-containing complex 5.1.
5.2 Results and Discussion
Biphenyl-functionalized cryptate 5.1 was designed based on the structure of Gd3+based contrast agents that interact with HSA. These Gd3+-containing albumin-binding
contrast agents contain lipophilic aryl groups such as the biphenyl moiety that enable them
to interact with HSA.16–25 Therefore, I expected that the lipophilic biphenyl moiety in
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cryptate 5.1 would enable investigation of the effect of albumin binding on the relaxivity
of Eu2+ at different field strengths.
5.2.1 Influence of Magnetic Field on the Relaxivity of 5.1 and 5.1–HSA
The relaxivity, r1, of 5.1 in PBS in the presence and absence of HSA was measured at
multiple field strengths, and because not all of the magnets were capable of variabletemperature measurements, I separated data into Figure 5.2a and 5.2b so that
measurements obtained at each temperature could be compared. In the absence of HSA,
the r1 of 5.1 at 20 °C is higher at 7 and 9.4 T than at 3 T suggesting that this complex is
more efficient at ultra-high field strengths than at lower field strengths (Figure 5.2a).
However, I found that the r1 values at 3 and 11.7 T were not different (Student t test).
Moreover, the relaxivity of 5.1 as a function of field strength is similar to other Eu2+containing cryptates in the same conditions.7 In the presence of HSA (4.5% w/v), the
relaxivity of 5.1 decreased by 24.8 ± 0.6% to 40.2 ± 0.2% at field strengths of 3, 7, 9.4, and
11.7 T (Figure 5.2a). However, at 37 °C and 1.4 T, the r1 of 5.1 in the presence of albumin
was 171 ± 11% higher than in the absence of HSA (Figure 5.2b). An increase of 218% in
relaxivity (measured at 37 °C and 0.47 T MHz) was reported by McMurry and coworkers
for a Gd3+-containing complex functionalized with biphenyl in the presence of albumin.25
McMurry’s report and the relaxation data of 5.1 at 1.4 T indicate that the observed
relaxation enhancement of 5.1 in the presence of HSA is likely due to the interaction of the
biphenyl moiety of Eu2+cryptate with albumin.30 However, the relaxivity of 5.1 was
15.2 ± 0.5% and 49.8 ± 0.2% lower in the presence of HSA at 37 °C and 9.4 T and 11.7 T,
respectively. The observed decreasing trend in relaxivity of 5.1 in the presence of HSA at
37 °C as a function of field strength is consistent with the trend obtained by calculating the
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relaxivity of a slowly rotating Eu2+-containing cryptate at multiple field strengths using the
Solomon–Bloembergen–Morgan equations (Figure 5.2b and Table 5.1).

Figure 5.2 (a) Proton longitudinal relaxivity (20 °C, pH = 7.4) of biphenyl-functionalized
cryptate 5.1 in the absence (○) and presence (□) of HSA as a function of magnetic field
strength. (b) Proton longitudinal relaxivity (37 °C, pH = 7.4) of biphenyl-functionalized
cryptate 5.1 in the absence (○) and presence (□) of HSA as a function of magnetic field
strength. Simulated relaxivity values (■) of a slowly rotating Eu2+-containing complex at
37 °C. Values at 1.4, 3, 7, and 11.7 T without HSA are from Ref. 6. HSA concentration
was 4.5% (w/v). Error bars represent standard error of the mean of 3–9 independently
prepared samples.
5.2.2 Albumin Titration
To better understand the effect of albumin on the relaxivity of 5.1, titration experiments
were performed using different percentages (2, 4.5, 6, 10, 15, and 25% w/v) of HSA while
keeping the concentration (1 mM) of cryptate 5.1 constant. In preparation of 5.1, two
equivalents of the biphenyl cryptand were used for each equivalent of Eu2+ to facilitate
metalation of the biphenyl cryptand; therefore, the samples 2, 4.5, 6, and 10% HSA have
an excess of biphenyl relative to HSA (HSA/5.1 < 1 except 10% HSA sample) and
samples with 15 and 25% HSA have a subcess of biphenyl relative to HSA (HSA/5.1 > 1).
The MR images (Figure 5.3a) of 5.1 with HSA/5.1 ratios less than one have higher signal
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intensities as compared to the images of samples with HSA/5.1 ratios greater than 1. To
quantify this observation, the proton longitudinal relaxation rate, 1/T1, of the sample with
the lowest HSA/5.1 ratio is 102.7 ± 0.3% higher than the sample with the highest
HSA/5.1 ratio and 47.0 ± 0.2% higher than the other sample (15% HSA) that has an excess
of HSA relative to biphenyl (Figure 5.3b). The difference in signal intensity and
1/T1 values among the samples indicate that the presence of albumin affects the relaxivity
of complex 5.1 and does not translate to a higher signal intensity and higher efficacy
of 5.1 at ultra-high fields. These observations support the relaxivity measurements
described in Figure 5.1.
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Figure 5.3 (a) T1-weighted MR images of albumin-containing solutions of biphenylfunctionalized cryptate 5.1 at 7 T and 20 °C. The diameter of the tubes that were used for
imaging

was

6 mm.

Imaging

parameters

were TR = 21 ms; TE = 3.26 ms;

and

resolution = 0.27 × 0.27 × 2 mm3. (b) Proton longitudinal relaxation rate (20 °C, pH = 7.4)
as a function of % HSA at 7 T. The concentration of cryptate 5.1 was 1 mM. Error bars
represent standard error of the mean of three samples. aNo cryptate.
5.2.3 17O NMR Spectroscopy
To explain the observations of relaxivity, I performed variable-temperature 17O NMR
measurements using a sample of 5.1 in PBS and 5.1 in PBS with 25% HSA. I chose 25%
HSA because the majority of 5.1 was expected to be bound to albumin at this percentage,25
and the 17O NMR data obtained from this sample would be representative of the molecular
properties of cryptate 5.1 that is bound to HSA. The molecular properties that influence
relaxivity that were studied using variable-temperature 17O NMR spectroscopy were the
residence lifetime of bound water molecules, τm298; the water-exchange rate, kex298 =
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1/τm298; and the number of inner-sphere water molecules, q (Table 5.1). While the
residence lifetime of bound water of cryptate 5.1 was not different (Student t test) in the
presence and absence of albumin, the number of inner-sphere water molecules was reduced
from two to one upon addition of albumin indicating that the observed decrease in
relaxivity for cryptate 5.1 in the presence of albumin at 3, 7, 9.4, and 11.7 T is likely
caused by the displacement of inner-sphere water molecules from the Eu2+ complex.
Moreover, the residence lifetime of bound water was not different in the presence or
absence of albumin suggesting that protein side chains do not hinder the remaining bound
water molecule from exchanging with the bulk solvent. With the water-exchange rate and
the number of inner-sphere water molecules of 5.1 in the presence of HSA remaining
constant at different field strengths, the relaxivity enhancement observed at 1.4 T likely
can be attributed to the enhanced contribution of rotational correlation rate at this field
strength.
Table 5.1 Results of 17O NMR experiments of cryptate 5.1 with and without albumin.

a

5.1a

5.1–HSAb

τm298 (ns)

48 ± 4

40 ± 7

kex298 (108 s–1)

0.21

0.25

q

2

1

∆H (kJ/mol)

70 ± 2

62 ± 8

Reference 6, bHSA concentration was 25% (w/v)

5.3 Conclusions
The relaxation profile of Eu2+-containing cryptate 5.1 in the absence of albumin shows
that cryptate 5.1 is more efficient at higher field strengths (7 and 9.4 T) than at lower field
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strengths (1.4 and 3 T). MR images and 1/T1 values of samples with different
HSA/5.1 ratios suggest that possible interaction of 5.1 with HSA occurs, but this
interaction does not lead to an increase in relaxivity of Eu2+ at higher field strengths
(⩾3 T). However, in the presence of albumin, an increase in relaxivity of 5.1 is only
observed at 1.4 T likely due to decreased rotational correlation rate values, and a decrease
in relaxivity was observed at 3, 7, 9.4, and 11.7 T because of a decreased watercoordination number. These data are in agreement with calculations made using the
Solomon–Bloembergen–Morgan equations. Studies using different lengths of linkers
between the biphenyl and cryptate could provide a good insight on the influence of
albumin interaction on the relaxivity of cryptate 5.1. Also, binding a Eu2+-containing
cryptate to different sizes of macromolecules could provide a better understanding on the
effect of macromolecular binding on the relaxivity of Eu2+-containing cryptates at higher
fields. These studies are currently underway in our laboratory.
5.4 Experimental Section
5.4.1 Materials
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Biphenyl-functionalized cryptand and
cryptate 5.1 were prepared following a published procedure presented in chapter 3 of this
thesis.
5.4.2 Concentrations
Samples for inductively coupled plasma mass spectrometry (ICP-MS) were diluted
using aqueous nitric acid (2% v/v). Standard solutions were prepared by serial dilution of a
Eu standard (high-purity standards). ICP-MS measurements were conducted on a PE Sciex
Elan 9000 ICP-MS instrument with a cross-flow nebulizer and Scott-type spray chamber.
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5.4.3 Preparation of HSA samples
Stock solutions of HSA (30% w/v) and (35% w/v) were prepared by dissolving 300
and 350 mg of HSA, respectively in 1 mL of 1× degassed phosphate buffered saline (PBS).
An aliquot of the stock HSA solution was added to a solution of 5.1 in degassed PBS to
produce the desired concentrations of 5.1 and HSA.
5.4.4 Preparation of Sr2+ analogue of 5.1
A degassed aqueous solution of SrCl2 (1 equiv, 41.2 mM) was mixed with a degassed
aqueous solution of the biphenyl cryptand (2 equiv, 34.2 mM). The resulting mixture
(1 mM SrCl2 and 2 mM cryptand) was stirred for 12 h at ambient temperature under Ar.
Degassed PBS (10×) was added to make the entire reaction mixture 1× in PBS, and stirring
was continued for 30 min. The concentration of Sr in the resulting solution was verified by
ICP-MS.
5.4.5. T1 and relaxivity measurements
Longitudinal relaxation times, T1, were measured using standard recovery methods
with a Bruker Minispec mq 60 (1.4 T) at 60 MHz and 37 °C; a Varian Unity 400 (9.4 T) at
400 MHz and 20 and 37 °C; and a Varian 500S (11.7 T) at 500 MHz and 20 and 37 °C.
The slope of a plot of 1/T1 versus concentration of Eu was used to calculate relaxivity.
Four to six different concentrations of Eu (0–10 mM) were used, and measurements were
repeated 3–9 times with independently prepared samples.
Susceptibility weighted imaging (SWI) was performed at 3 (Siemens TRIO) and 7 T
(ClinScan)

using

volume

coils.

The

follows: TR = 37 ms, TE = 5.68–31.18 ms,
and TR = 21 ms, TE = 3.26–15.44 ms,

and

acquisition

parameters

were

as

resolution = 0.5 × 0.5 × 2 mm3 for

3 T;

resolution = 0.27 × 0.27 × 2 mm3 for

7 T.

and

Multiple flip angles (5, 10, 15, 20, 25, and 30°) were used in the SWI experiments to allow
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for the determination of longitudinal relaxation time, T1.31 MR images were processed
using SPIN software (SVN Revision 1751). Matlab (7.12.0.635 R2011a) was used to
generate effective transverse relaxation time, T2∗, and corrected T1 maps. The 1/T1 values
from the corrected T1 maps were plotted versus the concentration of Eu in the samples to
calculate longitudinal relaxivities, r1, as previously reported in chapter 3 of this document.6
5.4.6. Variable-temperature 17O NMR experiments
Variable-temperature 17O NMR measurements of solutions of 5.1-HSA (1 mM 5.1,
25% HSA) and its Sr2+analogue (1 mM Sr2+-cryptate, 25% HSA) in degassed PBS (pH
7.4) were obtained on a Varian-500S (11.7 T) spectrometer. 17O-enriched water (10%
H217O, Cambridge Isotope Laboratories, Inc.) was added to samples to yield 1% 17O
enrichment. Transverse 17O relaxation rates were measured at 15, 25, 30, 35, 40, 45, and
50 °C. The Sr2+ analogue of 5.1-HSA was used as diamagnetic reference. A/ħ was fixed to
−4.1 × 10−6 rad/s.32 The least-squares fits of the 17O NMR relaxation data were calculated
using Origin software (8.0951 B951) following published procedures.33
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Table 5.2. Variable-temperature 17O NMR Data for Cryptate 5.1 and Sr2+ analogue of 5.1
in the presence of albumin.
Temperature (°C)

Linewidth of 17OH2 (Hz)
Sr2+ analogue of 5.1–HSA

5.1–HSA

50

57.85

60.44

45

65.03

68.09

40

73.78

77.40

35

84.57

89.24

30

96.26

102.35

25

111.44

119.16

15

151.97

160.28
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Figure 5.4. Variable-temperature
albumin.

17

O NMR Fittings for cryptate 5.1 in the presence of
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Chapter Six
Summary of Findings and Future Outlook
6.1 Summary of Findings
Magnetic resonance imaging (MRI) cannot always differentiate pathological from
healthy tissues, and therefore contrast agents are used to enhance image contrast. However,
the contrast-enhancing ability of clinically approved contrast agents decreases dramatically
at higher field strengths where better resolution and shorter scan times are accessible.
Therefore, there is a need to develop T1-reducing (positive) contrast agents that perform
well in the ultra-high field strength regime. This thesis describes my efforts with respect to
the coordination chemistry necessary to pursue an answer to this need.
I measured the relaxivity of small Eu2+-containing cryptates at field strengths that
are commonly used for clinical imaging and at field strengths that are used in preclinical
research. These studies demonstrated that these cryptates have higher relaxivity at ultrahigh field strengths relative to lower fields. In addition, these cryptates showed higher
efficiency at high and ultra-high field strengths relative to a clinically approved contrast
agent, gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate. Because of
these promising results, I also measured the relaxivity of small Eu2+-containing cryptates at
different temperatures and pH values. Relaxivity data showed that the contrast-enhancing
ability of these cryptates decreases as temperature increases, as predicted by theory, but is
not affected by changes in pH under physiologically relevant range.
The relaxometric studies described in this thesis demonstrated the basis of using
Eu2+-containing cryptates as contrast agents at ultra-high field strength MRI. Through my
studies, the scientific community is able to gain additional understanding of the
performance of Eu2+-containing cryptates at field strengths accessible to clinical and
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preclinical imaging. This knowledge should aid in the design of more efficient Eu 2+containing cryptates.
To explain the results of my relaxometric experiments, I performed variabletemperature

17

O NMR and electron paramagnetic resonance (EPR) spectroscopy. These

spectroscopic techniques are crucial in understanding the influence of molecular
parameters including the number of inner-sphere water molecules, water-exchange rate,
electron-spin relaxation times, and rotational-correlation rate to the relaxivity of Eu2+containing cryptates. These experiments demonstrated the presence of two inner-sphere
water molecules in each cryptate and near-optimal water-exchange rates for field strengths
above 3 T. Both of these properties are desirable features of an effective contrast agent. In
addition to the determination of the number of inner-sphere water molecules and waterexchange rate, EPR measurements were performed to determine electronic parameters
including the g factor and transverse electronic relaxation time. With the relaxivity and
NMR and EPR data, rotational-correlation rates were estimated and were found to limit the
relaxivity of these small Eu2+-containing cryptates.
With the understanding that these cryptates can potentially serve as contrast agents
based on relaxivity data, I also determined the stability of these Eu2+-containing complexes
towards transmetallation in the presence of the biologically relevant metal ions Ca2+, Mg2+,
and Zn2+. This transmetallation experiment was important because of the toxicity of
unchelated Eu2+, the abundance of Ca2+and Mg2+ in plasma, and the tendency of Zn2+ to
chelate organic ligands. In this experiment, I found that amine-containing cryptates are
inert to transmetallation and have longer transmetallation half-lives compared to nonmacrocyclic, clinically approved Gd3+-containing complexes including gadolinium(III)
diethylenetriaminepentaacetate.
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Finally, because I observed that the efficiency of small molecular weight cryptates
increases with molecular weight, I studied the contrast-enhancing ability of a biphenylfunctionalized cryptate that can bind to macromolecules. I studied the relaxivity of this
system in the presence of human serum albumin at multiple field strengths, performed
albumin titration experiments, and used variable-temperature

17

O NMR and EPR

spectroscopies to understand the effect of albumin binding on the molecular parameters
that influence relaxivity. These studies revealed a decrease in relaxivity in the presence of
albumin that was likely due to the displacement of an inner-sphere water molecule.
However, an increase in relaxivity in the presence of albumin was observed at 1.4 T. This
change was attributed to the enhanced contribution of rotational correlation rate to
relaxivity. This work opens an avenue of research for understanding the effect of
macromolecular binding to the efficiency of these cryptates as contrast agents and to gain
an improved understanding of the relaxivity–molecular weight relationship for these
cryptates.
6.2 Future Outlook
The increase in relaxivity for Eu2+-containing cryptates at ultra-high field strengths
is one of a few examples of paramagnetic materials exhibiting an increase in relaxivity as
field strength increases in the ultra-high field strength regime. While the result is
interesting, it is not yet fully understood why this increase in relaxivity is observed for
these cryptates. Determining the relaxation profiles of other Eu2+-containing cryptates with
molecular weights of more than 500 Da could yield insight with respect to the relaxivity of
these cryptates. These studies could be achieved by binding cryptates to supramolecular
systems or by covalently attaching cryptates to polymers. Relaxation profiles of the
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resulting macromolecular systems could be determined by nuclear magnetic relaxation
dispersion (NMRD) relaxometry and high-field NMR spectroscopy.
In addition to the relaxometric studies in the preceding chapters, I synthesized
dimeric and trimeric ligands to gain an understanding of the relaxivity–molecular weight
relationship for Eu2+-containing cryptates. However, obtaining pure ligands using size
exclusion chromatography remained elusive, and unequivocal characterization of
metalated ligands is a challenging task. I suggest using reverse phase chromatography as
an alternative way of purifying these oligomers. Also, dialysis using membranes of 500–
1000 molecular weight cutoff could also be used for purification. The metalated ligands
could be characterized by elemental analysis. Differentiating bimetalated ligands to
monometalated and unmetalated ligands could be made by comparing the sulfur to
europium ratio in the elemental analysis. This characterization requires the metalation to be
performed, using an excess of europium(II) to facilitate metalation, in water rather than in
phosphate buffered saline. After metalation, dialysis should be performed using 500 Da
molecular cutoff to remove unchelated europium.
To further boost the utility of Eu2+-containing cryptates, I studied the relaxivity of a
biphenyl-functionalized cryptate in the presence of human serum albumin. The albumin
studies demonstrated that the decrease in relaxivity for the biphenyl-functionalized cryptate
in the presence of albumin could be ascribed to displacement of an inner-sphere water
molecule as indicated by the variable-temperature 17O NMR spectroscopy results. This loss
of an inner-sphere water molecule could be due to the short linker that connects the
biphenyl moiety and Eu2+ in the cryptand. The use of longer linkers could prevent innersphere water molecules from being displaced from the complex.
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In addition to the transmetallation studies that I performed in the presence of
physiological cations, it is also important to study the effect of physiologically relevant
anions such as citrate, malonate, carbonate, or lactate on the kinetic stability of Eu2+containing cryptates. These ions are of particular concern if the cryptates have net positive
charges because the affinity of the anions would be higher. While the presence of
phosphate does not displace inner-sphere water molecules from the cryptates that I studied,
other anions could compete with the cryptand for Eu2+, resulting in insoluble adducts. The
transmetallation experiments described in this thesis could be adapted to study anions, and
the results of these transmetallation studies would provide an understanding of the effect of
different anions on the stability of Eu2+-containing cryptates.
Finally, it is important to investigate the toxicity profile of the synthesized Eu2+containing cryptates by determining the maximum tolerated dose. These studies would
help determine the effect of cryptate structure on toxicity. In addition, the use of
antioxidants in the toxicity studies could provide information regarding the extent that
antioxidants prolong the oxidation half-life of cryptates and lessen toxicity. Preliminary in
vitro studies of cryptates in the presence of reduced glutathione demonstrated that reduced
glutathione prolongs the oxidation half-life Eu2+-containing cryptates. The information that
will be obtained from toxicity studies of Eu2+-containing cryptates would be useful for in
vivo applications.
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APPENDIX A
MATLAB CODES FOR GENERATING T2* AND T1 MAPS
T2*:
% function [T2map error_estimatemap]=flash_fit(fa,s,tr)
% s is the 3D matrix of # of slices equal to the nsumber of flip angles.
clear all;
clc
format long;
h=msgbox(' --------Please enter the information Asked for ---------');
waitfor(h);
rows=input('Enter Matrix size # ROWS: ');
cols=input('Enter Matrix size # COLS: ');
echonumber=input('Enter number of echoes: ');
slices=input('Enter the number of slices in each echo images: ');
s.fpathname=[];
%%%%%%%%%% FILE INFORMATION INPUT
for i=1:echonumber
disp(' ');disp(' ');disp(' ')
display('Select the first file in the series you want to calculate T2*');
[fname, path]=uigetfile('C:\Archives\Ang Doktorado\Projects\Imaging
Experiments\2011 05 20 Phantom Imaging 3T\DICOM\511Echo_SWI_FA5_.5x.5x2\TEsorted\*.*');
s(i).fpathname=strcat(path,fname)
disp(' ');disp(' ');disp(' ');
TE(i)=input('\n Please enter the Corresponding echo time (TE) : ');
end
mm=zeros(rows,cols);
mm1=zeros(rows,cols);
%%%%%%%%%%%%%%%%%% ACTUAL CALCULATION WITH ALPHA MAP COMPENSATION INCLUDED
for i=1:slices
mat=zeros(rows,cols); % IMAGE MATRIX SIZE
xmat=zeros(size(TE,2),rows,cols); % IMAGE MATRIX SIZE
ymat=zeros(size(TE,2),rows,cols); % IMAGE MATRIX SIZE
for j=1:echonumber
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if s(j).fpathname(size(s(j).fpathname,2)-7)=='-'
firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)6))*100+str2num(s(j).fpathname(size(s(j).fpathname,2)5))*10+str2num(s(j).fpathname(size(s(j).fpathname,2)-4));
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)7)),num2str(firstnum+i-1),'.dcm'));
elseif s(j).fpathname(size(s(j).fpathname,2)-6)=='-'
firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)5))*10+str2num(s(j).fpathname(size(s(j).fpathname,2)-4));
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)6)),num2str(firstnum+i-1),'.dcm'));
else s(j).fpathname(size(s(j).fpathname,2)-5)=='-'
firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4));
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)5)),num2str(firstnum+i-1),'.dcm'));
end
ymat(j,:,:)=log(mat);
xmat(j,:,:)=-TE(j);
%

end

end
clear

mat tmps tmpt;

num=echonumber*sum((xmat.*ymat),1)-(sum(xmat,1).*sum(ymat,1));
din=echonumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2;
b1=num./din;
b2=(1/echonumber)*(sum(ymat,1)-b1.*sum(xmat,1));
T2map=(1./b1);
%
T1map=-tr./(log(b1)); %%%%% TR OF THE EXPERIMENT
mm(:,:)=T2map(1,:,:);
clear T2map;
T2map=mm;
%
%
%
%

mm(:,:)=echoimagemat(1,:,:);
mm1(:,:)=echoimagemat(2,:,:);
T2_error= (T2map/dTE).*sqrt( (sigma1./mm).^2 + (sigma2./mm1).^2 );

curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)7)),'T2_map_mult10-',num2str(i),'.ima');
writeima(curntfname, T2map*100);
%
dicomwrite(T2map*100,curntfname);
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%
curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)7)),'T2_errmap_mult10-',num2str(i),'.dcm');
%
%
writeima(curntfname, T2_error*10);
%
dicomwrite(T2map,curntfname);
end

T1 map (with T2* correction):
% function [T1map error_estimatemap]=flash_fit(fa,s,tr)
% s is the 3D matrix of # of slices equal to the number of flip angles.
clear all;
clc
format long;
h=msgbox(' --------Please enter the information Asked for ---------');
waitfor(h);
rows=input('Enter Matrix size # ROWS: ');
cols=input('Enter Matrix size # COLS: ');
TE=input('Enter Echo-time: ');
fanumber=input('Enter number of flip angles: ');
slices=input('Enter the number of slices in the Flip angle images: ');
s.fpathname=[];
display('Please input the T2starcorrection file (.ima)');
[fnameT2star, pathT2star]=uigetfile('C:\Archives\Ang
Doktorado\Projects\Imaging Experiments\2011 05 20 Phantom Imaging
3T\DICOM\*.*');
fpathnameT2star=strcat(pathT2star,fnameT2star)
t2starcorrection=showima(fpathnameT2star);

%%%%%%%%%% FILE INFORMATION INPUT
for i=1:fanumber
disp(' ');disp(' ');disp(' ')
display('Select the first file in the series you want to calculate T1');
[fname, path]=uigetfile('C:\Archives\Ang Doktorado\Projects\Imaging
Experiments\2011 05 20 Phantom Imaging 3T\DICOM\*.*');
s(i).fpathname=strcat(path,fname)
disp(' ');disp(' ');disp(' ');
fa(i)=input('\n Please enter the Corresponding Flip angle:
');
end
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% disp(' ');disp(' ');
% disp('Select the corresponding first reference flip angle image for
normalization:');
% fa=(fa)*(pi/180);
% [fname, path]= uigetfile('E:\Data_OM\Rahul1.5T_LOW FA data\');
% str=strcat(path,fname);
%
% disp(' ');disp(' ');
% normfactor=input('Enter the normalization peak/mode/mean value from the
normalization image: ');
tr=input('Enter TR of the experiment: ');
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
mm=zeros(rows,cols);

% flag=input(' ENTER 1 for alpha map normalisation: OR 2 for normal T1 map
calculation: ');
fa=fa*(pi/180);

%%%%%%%%%%%%%%%%%% ACTUAL CALCULATION WITH ALPHA MAP COMPENSATION INCLUDED
for i=1:slices
%
alphamap=zeros(rows,cols);% IMAGE MATRIX SIZE
mat=zeros(rows,cols); % IMAGE MATRIX SIZE
xmat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE
ymat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE
%
faimagemat=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE

for j=1:fanumber

if s(j).fpathname(size(s(j).fpathname,2)-5)=='-'
firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4));
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)5)),num2str(firstnum+i-1),'.dcm'));
mat(:,:)=mat./exp(-TE./t2starcorrection);
else
firstnum=str2num(s(j).fpathname(size(s(j).fpathname,2)-4))+10;
mat(:,:)=dicomread(strcat(s(j).fpathname(1,1:(size(s(j).fpathname,2)6)),num2str(firstnum+i-1),'.dcm'));
mat(:,:)=mat./exp(-TE./t2starcorrection);
end

faimagemat(j,:,:)=mat;
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tmps=sin(fa(j));
tmpt=tan(fa(j));
ymat(j,:,:)=mat./tmps;
xmat(j,:,:)=mat./tmpt;
end
clear

mat tmps tmpt;

num=fanumber*sum((xmat.*ymat),1)-(sum(xmat,1).*sum(ymat,1));
din=fanumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2;

b1=num./din;
b2=(1/fanumber)*(sum(ymat,1)-b1.*sum(xmat,1));

T1map=-tr./(log(b1)); %%%%% TR OF THE EXPERIMENT
mm(:,:)=T1map(1,:,:);
clear T1map;
T1map=mm;
% Error MATRIX calculation
yestimate=zeros(size(fa,2),rows,cols); % IMAGE MATRIX SIZE
for j=1:fanumber
num=b2.*sin(fa(j));
din=1-cos(fa(j)).*b1;
yestimate(j,:,:)=num./din;
end
sigma_y_error_estimate=sqrt((1/(fanumber-2))*sum((yestimatefaimagemat).^2,1));
din=fanumber*(sum(xmat.^2,1))-(sum(xmat,1)).^2;
error_b1=sigma_y_error_estimate.*sqrt(fanumber./din);
mm(:,:)=zeros(rows,cols);
mm(:,:)=din(1,:,:);
clear din;
din=mm;clear mm;

T1_error=(tr*error_b1)./(b1.*(log(b1)).^2);
rho_e2=b2./(1-b1);

mm(:,:)=zeros(rows,cols);
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mm(:,:)=T1_error(1,:,:);
clear T1_error error_b1;
T1_error=mm;

curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)-7)),'T1_map',num2str(i),'.ima');
writeima(curntfname, T1map);
curntfname=strcat(s(1).fpathname(1,(1:size(s(1).fpathname,2)7)),'T1_errmap_mult10-',num2str(i),'.ima');
writeima(curntfname, T1_error*10);

end

159

APPENDIX B
CACULATED RELAXIVITY OF 5.1 AND 5.1–HSA AT
DIFFERENT MAGNETIC FIELD STRENGTHS
Pertinent equations:
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) (
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The calculated relaxivity decreases from 1.4 T to 11.7 T (Table B.1). Assumptions made in the
calculations are that the electronic parameters, v and Δ2, do not change with magnetic field and that the
values of v and Δ2 that were measured at 0.34 T are valid at higher field strengths. It was also assumed
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that the R for the biphenyl-modified cryptate in the presence of HSA is the same as that of MS-325 in
the presence of HSA at 37 C.
Constants

References

m

4.0 × 10–8

this work

q

1

this work

γI

2.67 × 108

http://physics.nist.gov/cgi-bin/cuu/Value?gammap

g

2

http://physics.nist.gov/cgi-bin/cuu/Value?gem|search_for=all!

μB

9.27 × 10–24

http://physics.nist.gov/cgi-bin/cuu/Value?mub

rEu–H

3.22 × 10–10 L. Burai, É. Tóth, S. Seibig, R. Scopelliti, A. E. Merbach, Chem. Eur. J. 6
(2000) 3761–3770.

μo

1.00 × 10–7

http://physics.nist.gov/cgi-bin/cuu/Value?mu0

γS

1.76 × 1011

L. Burai, É. Tóth, S. Seibig, R. Scopelliti, A. E. Merbach, Chem. Eur. J. 6
(2000) 3761–3770.

R

1.33 × 10–8

MS-325 with HSA from P. Caravan, N. J. Cloutier, M. T. Greenfield, S.
A. McDermid, S. U. Dunham, J. W. M. Bulte, J. C. Amedio, Jr., R. J.
Looby, R. M. Supkowski, W. DeW. Horrocks, Jr., T. J. McMurry, R. B.
Lauffer, J. Am. Chem. Soc. 124 (2002) 3152–3162.

Δ2

2.10 × 1019

Eu2+[2.2.2]cryptate from L. Burai, R. Scopelliti, É. Tóth, Chem. Commun.
(2002) 2366–2367.

v

1.70 × 10–11

Eu2+[2.2.2]cryptate from L. Burai, R. Scopelliti, É. Tóth, Chem. Commun.
(2002) 2366–2367.
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Table B.1. Calculated relaxivity values of 5.1 in the presence of HSA at different field strengths
at 37 C.

Field Strength (T)

Relaxivity (mM–1s–1)

1.4

16.10

3

3.80

7

0.71

9.4

0.40

11.7

0.26
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this License at their sole discretion, for any reason or no reason, with a full refund payable to
you. Notice of such denial will be made using the contact information provided by you. Failure
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LIMITED LICENSE
The following terms and conditions apply only to specific license types:
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license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all
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version. A hyper-text must be included to the Homepage of the journal from which you are
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production process, you will receive an e-mail notice when your article appears on Elsevier’s
online service ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s
Digital Object Identifier (DOI). This number provides the electronic link to the published article
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A3. Copyright Permission for Eur. J. Inorg. Chem. 2012, 2012, 4550–4563.
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acknowledged for all or part of this Material. Any third party material is expressly excluded from this permission.
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may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, or any of the rights granted to you hereunder to any other person.
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Agreement. You agree that you own no right, title or interest in or to the Materials or any of the intellectual property rights therein. You shall have no rights hereunder other than the license as
provided for above in Section 2. No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors is granted hereunder, and you
agree that you shall not assert any such right, license or interest with respect thereto.
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY,
WITH RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY
OF MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH
WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement by you.
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, officers, agents and employees, from and against any actual or threatened claims,
demands, causes of action or proceedings arising from any breach of this Agreement by you.
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING
OR USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES),
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9. Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as
possible the same economic effect as the original provision, and the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.
10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of either party's right to enforce each and every term and condition of this
Agreement. No breach under this agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed by the party granting such waiver or consent.
The waiver by or consent of a party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach by such other
party.
11. This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's prior written consent.
12. Any fee required for this permission shall be non-refundable after thirty (30) days from receipt.
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process by registered or certified mail, return receipt requested, at the last known address of such party.
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Use by non-commercial users
For non-commercial and non-promotional purposes individual users may access, download, copy, display and redistribute to colleagues Wiley Open Access articles, as well as adapt, translate,
text- and data-mine the content subject to the following conditions:
 The authors' moral rights are not compromised. These rights include the right of "paternity" (also known as "attribution" - the right for the author to be identified as such) and "integrity" (the
right for the author not to have the work altered in such a way that the author's reputation or integrity may be impugned).
 Where content in the article is identified as belonging to a third party, it is the obligation of the user to ensure that any reuse complies with the copyright policies of the owner of that content.
 If article content is copied, downloaded or otherwise reused for non-commercial research and education purposes, a link to the appropriate bibliographic citation (authors, journal, article title,
volume, issue, page numbers, DOI and the link to the definitive published version on Wiley Online Library) should be maintained. Copyright notices and disclaimers must not be deleted.
 Any translations, for which a prior translation agreement with Wiley has not been agreed, must prominently display the statement: "This is an unofficial translation of an article that appeared
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ABSTRACT
STUDIES ON THE PHYSICOCHEMICAL PROPERTIES OF
Eu2+ CRYPTATES: IMPLICATIONS TO CONTRAST
AGENTS FOR MAGNETIC RESONANCE IMAGING
by
JOEL GARCIA

May 2013
Advisor: Professor Matthew J. Allen
Major: Chemistry
Degree: Doctor of Philosophy
Magnetic resonance imaging (MRI) is a powerful medical imaging technique that can be
enhanced using metal complexes called contrast agents. Most clinically approved contrast
agents contain Gd3+. However, the efficiency (also known as relaxivity) of these Gd3+containing complexes decreases as field strength increases, and in the ultra-high field
strength regime, the relaxivity of these complexes is decreased considerably. Because of
the slow water-exchange rate of most Gd3+-containing complexes (~106 s–1), I used Eu2+
instead of Gd3+ and adapted the ligand modification strategies that have been used for
Gd3+-containing contrast agents to my Eu2+-containing complexes. Eu2+ is isoelectronic to
Gd3+ and has fast water-exchange rate (~109 s–1); however, the propensity of Eu2+ to
oxidize in aerobic conditions limits its utility. Earlier work in the Allen lab demonstrated
that modified cryptands can stabilize the divalent state of Eu. Because of the favorable
properties of Eu2+ and the ability of cryptands to oxidatively stabilize Eu2+, I hypothesized
that Eu2+-containing cryptates could serve as good candidates for use as contrast agents for
MRI. Relaxometric studies revealed higher efficacy of small Eu2+-containing cryptates
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compared

to

the

clinically approved

contrast

agent

gadolinium(III)

1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetraacetate at ultra-high field strengths. Also, an increase
in relaxivity with increasing field strength was observed for these cryptates. Further, the
relaxivity of Eu2+-containing cryptates decreases as temperature increases, but is not
affected by changes in pH in a physiologically relevant range.
Variable-temperature 17O NMR and electron paramagnetic resonance spectroscopy
were used to understand these observations in relaxivity. Variable-temperature

17

O NMR

experiments revealed the presence of two inner-sphere water molecules and fast waterexchange rates (~107–108 s–1) for small Eu2+-containing cryptates. With the relaxivity and
17

O NMR and EPR data, rotational-correlation rates for these cryptates were estimated and

were found to limit relaxivity.
In addition to relaxometric studies, transmetallation experiments were performed in
the presence of Ca2+, Mg2+, and Zn2+ because of their relative abundance in plasma and the
affinity of these ions for ligands. The transmetallation experiments demonstrated that
amine-based cryptates are stable to transmetallation in the presence of Ca2+, Mg2+, and
Zn2+

and

are

more

stable

than

the

clinically

approved

gadolinium(III)

diethylenetriaminepentaacetate, a promising result for their potential use for in vivo
applications.
Because relaxivity of small Eu2+-containing cryptates increases with molecular
weight, I also investigated the effect of albumin on the relaxivity of a biphenyl-containing
cryptate. While relaxivity enhancement was observed in the presence of albumin at 1.4 T,
the relaxivity of the biphenyl-based cryptate in the presence of albumin at 3, 7, 9.4, and
11.7 T was lower compared to in the absence of albumin. This decrease in relaxivity was
attributed to a displacement of one inner-sphere water molecule upon protein binding.
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These studies of the physicochemical properties of Eu2+-containing cryptates
provide a better understanding of how relaxivity is influenced by molecular parameters
including the number of inner-sphere water molecules, water-exchange rate, and rotationalcorrelation rate for these cryptates and pave the way for designing more efficient Eu2+containing cryptates for use as contrast agents for MRI.
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